



AM

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C07K 14/705, C12N 15/12, 15/63, 15/70, 15/79		A1	(11) International Publication Number: WO 99/48921 (43) International Publication Date: 30 September 1999 (30.09.99)
(21) International Application Number: PCT/US99/06573 (22) International Filing Date: 25 March 1999 (25.03.99)		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/079,501 26 March 1998 (26.03.98) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicants (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Suite 350, 900 Welch Road, Palo Alto, CA 94304 (US). N.V. ORGANON [NL/NL]; Weth, Van Eschstraat 1, P.O. Box 20, NL-5340 BH Oss (NL).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HSUEH, Aaron, J., W. [US/US]; 25 Ryan Court, Stanford, CA 94305 (US). HSU, Sheau, Yu [-/US]; Apartment 40, 234 Escuela Avenue, Mountain View, CA 94040 (US). LIANG, Shan-Guang [CN/US]; 438 Ventura Avenue #9, Palo Alto, CA 94306 (US). VAN DER SPEK, Petrus, Johannes [NL/NL]; Bremelaan 10, NL-5342 HM Oss (NL).			
(74) Agent: FIELD, Bret, E.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).			
(54) Title: NOVEL MAMMALIAN G-PROTEIN COUPLED RECEPTORS HAVING EXTRACELLULAR LEUCINE RICH REPEAT REGIONS			
(57) Abstract			
<p>Isolated nucleotide compositions and sequences are provided for LGR4, LGR5 and LGR7 genes. The nucleic acid compositions find use in identifying homologous or related genes; in identifying endogenous ligands for these receptors; in producing compositions that modulate the expression or function of its encoded protein; for gene therapy; mapping functional regions of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity <i>in vivo</i> is used for prophylactic and therapeutic purposes.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL MAMMALIAN G-PROTEIN COUPLED RECEPTORS HAVING EXTRACELLULAR LEUCINE RICH REPEAT REGIONS

INTRODUCTION

5 Field of the Invention

The field of this invention is the G-protein coupled receptor family of proteins.

Background

Gonadotropins (Luteinizing hormone, LH; follicle stimulating hormone, FSH; chorionic gonadotropin, CG) and thyrotropin (TSH)) are essential for the growth and 10 differentiation of gonads and thyroid gland, respectively. These glycoprotein hormones bind specific target cell receptors on the plasma membrane to activate the cAMP-protein kinase A pathway.

The receptors for LH, FSH and TSH belong to the large G-protein-coupled, seven-trans-membrane protein family but are unique in having a large N-terminal extra-cellular 15 (ecto-) domain containing leucine-rich repeats important for interaction with large glycoprotein ligands. Studies suggest that in these receptors, the extra-cellular leucine rich repeat region serves as a "baseball glove" which efficiently catches its corresponding large hormone ligand and optimally orients it for interaction with the seven trans-membrane-helical domain of the receptor.

20 Because hormones and receptors play a prominent role in a variety of physiological processes, there is continued interest in the identification of novel receptors and their ligands, as well as the genes encoding the same.

Relevant Literature

References of interest include: el Tayar, N., "Advances in the Molecular 25 Understanding of Gonadotropins-Receptors Interactions," Mol. Cell. Endocrinol. (December 20, 1996) 125: 65-70; Bhowmick et al., "Determination of Residues Important in Hormone Binding to the Extracellular Domain of the Luteinizing Hormone/Chorionic Gonadotropin Receptor by Site-Directed Mutagenesis and Modeling," Mol. Endocrinol. (September 1996) 10: 1147-1159; Thomas et al., "Mutational Analyses of the 30 Extracellular Domain of the Full-Length Lutropin/Choriogonadotropin Receptor Suggest Leucine-Rich Repeats 1-6 are Involved in Hormone Binding," Mol. Endocrinol. (June 1996) 10:760-768; Segaloff & Ascoli, "The Gonadotropin Receptors: Insights from the

Cloning of their cDNAs." Oxf. Rev. Reprod. Biol. (1992) 14: 141-168; Braun et al., "Amino-Terminal Leucine-Rich Repeats in Gonadotropin Receptors Determine Hormone Selectivity," EMBO J (July 1991) 10: 1885-1890; and Segaloff et al., "Structure of the Lutropin/Choriogonadotropin Receptor," Recent Prog. Horm. Res. (1990) 46: 261-301.

5

SUMMARY OF THE INVENTION

Three novel mammalian G-protein coupled receptors having extra-cellular leucine rich repeat domains, i.e. LGR4, LGR5 and LGR7, and polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. The subject 10 proteins, polypeptide and nucleic acid compositions find use in a variety of different applications, including the identification of homologous or related genes; the production of compositions that modulate the expression or function of the subject proteins; in the identification of endogenous ligands for the subject orphan receptors; in the generation of functional binding proteins for the neutralization of the actions of endogenous ligands; in 15 gene therapy; in mapping functional regions of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity *in vivo* is used for prophylactic and therapeutic purposes, and the like.

BRIEF DESCRIPTION OF THE FIGURES

- 20 Fig. 1 provides the nucleotide and amino acid sequence for human LGR4.
Fig. 2 provides the nucleotide and amino acid sequence for human LGR5.
Fig. 3 provides the nucleotide and amino acid sequence for human LGR7, long form.
Fig. 4 provides the nucleotide and amino acid sequence for human LGR7, short 25 form.
Fig. 5 provides an alignment comparison of the long and short forms of LGR7.
Figs. 6 provides a comparison of deduced amino acid sequence of LGR4 and 5 cDNAs and those encoding FSH and LH receptors.

30

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Novel mammalian G-protein coupled receptors having extra-cellular leucine rich repeat regions (i.e. LGR4, LGR5 and LGR7) and polypeptide compositions related thereto, as well as nucleic acid compositions encoding the same, are provided. The 5 subject polypeptide and/or nucleic acid compositions find use in a variety of different applications, including the identification of homologous or related genes; for the identification of endogenous ligands for these novel receptors; the production of compositions that modulate the expression or function of the receptors; for gene therapy; for mapping functional regions of the receptors; in studying associated physiological 10 pathways; for *in vivo* prophylactic and therapeutic purposes; as immunogens for producing antibodies; in screening for biologically active agents; and the like.

Before the subject invention is further described, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as 15 variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

20 In this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

25 CHARACTERIZATION OF LGR4, LGR5 AND LGR7

LGR4, LGR5 and LGR7 are novel mammalian receptors of the G-protein coupled, seven trans-membrane family of proteins, specifically the subfamily of G-protein coupled seven trans-membrane proteins which are characterized by the presence of extra-cellular leucine rich repeat regions. As such, these proteins have trans-membrane segments and 30 extra-cellular regions similar to those found in the known LH, FSH, and TSH receptors. In other words, these proteins have both a G-protein coupled seven trans-membrane region

and a leucine rich repeat extra-cellular domain. The N-terminal extra-cellular domains of these proteins also show high homology with Drosophila Slit and Toll proteins having leucine rich repeats. These proteins are expressed in diverse tissues.

The human LGR4 gene has a nucleotide sequence as shown in SEQ ID NO:01.

- 5 The human LGR4 gene product has an amino acid sequence as shown in SEQ ID NO:02. LGR4 is expressed in a plurality of different tissue types, including ovary, testis, adrenal, placenta, liver, kidney and intestine.

The human LGR5 gene has a nucleotide sequence as shown in SEQ ID NO:03.

- 10 The LGR5 gene product has an amino acid sequence as shown in SEQ ID NO:04. LGR5 has been found to be mainly expressed in muscle, placenta and spinal cord tissue.

The human LGR7 gene encodes multiple splicing variants, each of which contains a multitude of cysteine-rich low density lipoprotein (LDL) binding motifs at the N-terminus in addition to the leucine rich repeat region. The longer forms of LGR-7 have a higher similarity than shorter forms of LGR-7 to snail LGR in the trans-membrane domain
15 and the N-terminal LDL binding domain. The overall structure of both the long and short forms of LGR-7 is similar to that of the LH receptor. The human LGR7 short form gene has a nucleotide sequence as shown in SEQ ID NO:05. The LGR7 short form gene product has an amino acid sequence as shown in SEQ ID NO:06. The human LGR7 long form gene has a nucleotide sequence as shown in SEQ ID NO:07. The LGR7 long form
20 gene product has an amino acid sequence as shown in SEQ ID NO:08. LGR7 is expressed in multiple tissues, including testis, ovary, prostate, intestine and colon.

IDENTIFICATION OF *LGR4*, *LGR5* AND *LGR7* SEQUENCES

- Homologs of *LGR4*, *LGR5* and *LGR7* are identified by any of a number of methods. A fragment of the provided cDNA may be used as a hybridization probe against
25 a cDNA library from the target organism of interest, where low stringency conditions are used. The probe may be a large fragment, or one or more short degenerate primers.

Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 6×SSC (0.9 M sodium chloride/0.09 M
30 sodium citrate) and remain bound when subjected to washing at 55°C in 1×SSC (0.15 M sodium chloride/0.015 M sodium citrate). Sequence identity may be determined by

hybridization under stringent conditions, for example, at 50°C or higher and 0.1×SSC (15 mM sodium chloride/0.15 mM sodium citrate). Nucleic acids having a region of substantial identity to the provided *LGR4*, *LGR5* and/or *LGR7* sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided sequences under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes may be any species, e.g., primate species, particularly human; rodents, such as rats and mice; canines; felines; bovines; ovines; equines; yeast; nematodes; etc.

Between mammalian species, e.g., human and mouse, homologs have substantial sequence similarity, e.g. at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990), *J. Mol. Biol.* **215**:403-10. Unless specified otherwise, all sequence analysis numbers provided herein are as determined with the BLAST program using default settings. The sequences provided herein are essential for recognizing *LGR4*, *LGR5* and *LGR7*-related and homologous proteins in database searches.

LGR4, *LGR5* and *LGR7* NUCLEIC ACID COMPOSITIONS

Nucleic acids encoding *LGR4*, *LGR5* and *LGR7* may be cDNA or genomic DNA or a fragment thereof. The terms “*LGR4* gene,” “*LGR5* gene” and “*LGR7* gene” shall be intended to mean the open reading frame encoding specific *LGR4*, *LGR5* and *LGR7* polypeptides, and *LGR4*, *LGR5* and *LGR7* introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene may be introduced into an appropriate vector for extra-chromosomal maintenance or for integration into a host genome.

The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, removed by nuclear RNA splicing, to create a continuous open reading frame encoding an LGR4, LGR5 and LGR7 protein.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It may further include the 3' and 5' untranslated regions found in the mature mRNA. It may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue and stage specific expression.

The sequence of the 5' flanking region may be utilized for promoter elements, including enhancer binding sites, that provide for developmental regulation in tissues where *LGR4*, *LGR5* and/or *LGR7* is expressed. The tissue specific expression is useful for determining the pattern of expression, and for providing promoters that mimic the native pattern of expression. Naturally occurring polymorphisms in the promoter region are useful for determining natural variations in expression, particularly those that may be associated with disease.

Alternatively, mutations may be introduced into the promoter region to determine the effect of altering expression in experimentally defined systems. Methods for the identification of specific DNA motifs involved in the binding of transcriptional factors are known in the art, e.g. sequence similarity to known binding motifs, gel retardation studies, etc. For examples, see Blackwell *et al.* (1995), *Mol. Med.* **1**:194-205; Mortlock *et al.* (1996), *Genome Res.* **6**:327-33; and Joulin and Richard-Foy (1995), *Eur. J. Biochem.* **232**:620-626.

The regulatory sequences may be used to identify *cis* acting sequences required for transcriptional or translational regulation of *LGR4*, *LGR5* and/or *LGR7* expression, especially in different tissues or stages of development, and to identify *cis* acting sequences and *trans*-acting factors that regulate or mediate *LGR4*, *LGR* and/or *LGR7* expression. Such transcription or translational control regions may be operably linked to an *LGR4*, *LGR5* or *LGR7* gene in order to promote expression of wild type or altered *LGR4*, *LGR5* or *LGR7* or other proteins of interest in cultured cells, or in embryonic, fetal or adult tissues, and for gene therapy.

The nucleic acid compositions of the subject invention may encode all or a part of the subject polypeptides. Double or single stranded fragments may be obtained of the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. For the most part, DNA fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and may be at least about 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening probes, etc. Larger DNA fragments, i.e. greater than 100 nt are useful for production of the encoded polypeptide. For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art. It is preferable to choose a pair of primers that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA, and will prime towards each other.

The *LGR4*, *LGR* and *LGR7* genes are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include an *LGR4*, *LGR5* or *LGR7* sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", i.e. flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The DNA may also be used to identify expression of the gene in a biological specimen. The manner in which one probes cells for the presence of particular nucleotide

sequences, as genomic DNA or RNA, is well established in the literature and does not require elaboration here. DNA or mRNA is isolated from a cell sample. The mRNA may be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences. Alternatively, the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, *e.g.* nitrocellulose, nylon, *etc.*, and then probed with a fragment of the subject DNA as a probe. Other techniques, such as oligonucleotide ligation assays, *in situ* hybridizations, and hybridization to DNA probes arrayed on a solid chip may also find use. Detection of mRNA hybridizing to the subject sequence is indicative of *LGR4*, *LGR5* and/or *LGR7* gene expression in the sample.

The sequence of an *LGR4*, *LGR5* or *LGR7* gene, including flanking promoter regions and coding regions, may be mutated in various ways known in the art to generate targeted changes in promoter strength, sequence of the encoded protein, *etc.* The DNA sequence or protein product of such a mutation will usually be substantially similar to the sequences provided herein, *i.e.* will differ by at least one nucleotide or amino acid, respectively, and may differ by at least two but not more than about ten nucleotides or amino acids. The sequence changes may be substitutions, insertions, deletions, or a combination thereof. Deletions may further include larger changes, such as deletions of a domain or exon. Other modifications of interest include epitope tagging, *e.g.* with the FLAG system, HA, *etc.* For studies of subcellular localization, fusion proteins with green fluorescent proteins (GFP) may be used.

Techniques for *in vitro* mutagenesis of cloned genes are known. Examples of protocols for site specific mutagenesis may be found in Gustin *et al.* (1993), *Biotechniques* **14**:22; Barany (1985), *Gene* **37**:111-23; Colicelli *et al.* (1985), *Mol. Gen. Genet.* **199**:537-9; and Prentki *et al.* (1984), *Gene* **29**:303-13. Methods for site specific mutagenesis can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, CSH Press 1989, pp. 15.3-15.108; Weiner *et al.* (1993), *Gene* **126**:35-41; Sayers *et al.* (1992), *Biotechniques* **13**:592-6; Jones and Winistorfer (1992), *Biotechniques* **12**:528-30; Barton *et al.* (1990), *Nucleic Acids Res* **18**:7349-55; Marotti and Tomich (1989), *Gene Anal. Tech.* **6**:67-70; and Zhu (1989), *Anal Biochem* **177**:120-4. Such mutated genes may

be used to study structure-function relationships of LGR4, LGR5 and/or LGR7, or to alter properties of the protein that affect its function or regulation.

LGR4, LGR5 and LGR7 POLYPEPTIDES

5 Also provided by the subject invention are LGR4, LGR5 and LGR7 polypeptide compositions. The term polypeptide composition as used herein refers to both the full length proteins as well as portions or fragments thereof. Also included in this term are variations of the naturally occurring proteins, where such variations are homologous or substantially similar to the naturally occurring protein, be the naturally occurring protein 10 the human protein, mouse protein, or protein from some other species which naturally expresses an LGR4, LGR5 or LGR7 protein, usually a mammalian species. A candidate homologous protein is substantially similar to an LGR4, LGR5 or LGR7 protein of the subject invention, and therefore is an LGR4, LGR5 or LGR7 protein of the subject invention, if the candidate protein has a sequence that has at least about 80%, usually at 15 least about 90% and more usually at least about 98% sequence identity with an LGR4, LGR5 or LGR7 protein, as measured by BLAST, supra. In the following description of the subject invention, the term "LGR4, LGR5 or LGR7-protein" is used to refer not only to the human LGR4, LGR5 or LGR7 protein, but also to homologs thereof expressed in non-human species, e.g. murine, rat and other mammalian species.

20 The subject gene may be employed for producing all or portions of LGR4, LGR5 and LGR7 polypeptides. By "LGR4 polypeptide/protein", "LGR5 polypeptide/protein," and "LGR7 polypeptide/protein" is meant an amino acid sequence encoded by an open reading frame (ORF) of *LGR4*, *LGR5* and *LGR7* genes, including the full-length native polypeptide and fragments thereof, particularly biologically active fragments and/or 25 fragments corresponding to functional domains, e.g. extra-cellular regions; and including fusions of the subject polypeptides to other proteins or parts thereof, e.g. chimeric proteins. For expression, an expression cassette may be employed. The expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control 30 of the transcriptional initiation region, and a transcriptional and translational termination

region. These control regions may be native to an *LGR4*, *LGR5* or *LGR7* gene, or may be derived from exogenous sources.

Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding

- 5 heterologous proteins. A selectable marker operative in the expression host may be present. Expression vectors may be used for the production of fusion proteins, where the exogenous fusion peptide provides additional functionality, i.e. increased protein synthesis, stability, reactivity with defined antisera, an enzyme marker, e.g. β -galactosidase, etc.

- 10 Expression cassettes may be prepared comprising a transcription initiation region, the gene or fragment thereof, and a transcriptional termination region. Of particular interest is the use of sequences that allow for the expression of functional epitopes or domains, usually at least about 8 amino acids in length, more usually at least about 15 amino acids in length, to about 25 amino acids, and up to the complete open reading frame
15 of the gene. After introduction of the DNA, the cells containing the construct may be selected by means of a selectable marker, the cells expanded and then used for expression.

LGR4, *LGR5* or *LGR7* polypeptides may be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. For large scale production of the protein, a unicellular organism, such as *E.*

- 20 *coli*, *B. subtilis*, *S. cerevisiae*, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, particularly mammals, e.g. COS 7 cells, may be used as the expression host cells. In some situations, it is desirable to express the *LGR4*, *LGR5* or *LGR7* gene in eukaryotic cells, where the *LGR4*, *LGR5* or *LGR7* protein will benefit from native folding and post-translational modifications. Small peptides can also
25 be synthesized in the laboratory. Polypeptides that are subsets of the complete *LGR4*, *LGR5* or *LGR7* sequence may be used to identify and investigate parts of the protein important for function or to raise antibodies directed against these regions.

- For production of the extracellular domain of the *LGR4*, *LGR5* or *LGR7* receptor, the anchored receptor approach as described in Osuga et al, Mol. Endocrinol. (1997) 11: 30 1659-1668 may be employed. Likewise, the chimeric receptor approach described in Kudo et al. J Biol. Chem. (1996) 271: 22470-22478 may be used.

Such peptides find use in the identification of endogenous ligands and in drug screening for agonists and antagonists using methods described in Osuga, *supra*. Solubilized extracellular domains find use as therapeutic agents, e.g. in the neutralization of the action of endogenous ligands.

With the availability of the protein or fragments thereof in large amounts, by employing an expression host, the protein may be isolated and purified in accordance with conventional ways. A lysate may be prepared of the expression host and the lysate purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. The purified protein will generally be at least about 80% pure, preferably at least about 90% pure, and may be up to and including 100% pure. Pure is intended to mean free of other proteins, as well as cellular debris.

The expressed LGR4, LGR5 and LGR7 polypeptides are useful for the production of antibodies, where short fragments provide for antibodies specific for the particular polypeptide, and larger fragments or the entire protein allow for the production of antibodies over the surface of the polypeptide. Antibodies may be raised to the wild-type or variant forms of LGR4, LGR5 or LGR7. Antibodies may be raised to isolated peptides corresponding to these domains, or to the native protein.

Antibodies are prepared in accordance with conventional ways, where the expressed polypeptide or protein is used as an immunogen, by itself or conjugated to known immunogenic carriers, e.g. KLH, pre-S HBsAg, other viral or eukaryotic proteins, or the like. Various adjuvants may be employed, with a series of injections, as appropriate. Both polyclonal and monoclonal antibodies may be produced. For monoclonal antibodies, after one or more booster injections, the spleen is isolated, the lymphocytes immortalized by cell fusion, and then screened for high affinity antibody binding. The immortalized cells, *i.e.* hybridomas, producing the desired antibodies may then be expanded. For further description, see Monoclonal Antibodies: A Laboratory Manual, Harlow and Lane eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, 1988. If desired, the mRNA encoding the heavy and light chains may be isolated and mutagenized by cloning in *E. coli*, and the heavy and light chains mixed to further enhance the affinity of the antibody. Alternatives to *in vivo* immunization as a

method of raising antibodies include binding to phage "display" libraries, usually in conjunction with *in vitro* affinity maturation.

DIAGNOSTIC USES

5 The subject nucleic acid and/or polypeptide compositions may be used to analyze a patient sample for the presence of polymorphisms associated with a disease state or genetic predisposition to a disease state. Biochemical studies may be performed to determine whether a sequence polymorphism in an *LGR4*, *LGR5* or *LGR7* coding region or control regions is associated with disease. Disease associated polymorphisms may include
10 deletion or truncation of the gene, mutations that alter expression level, that affect the activity of the protein, and the like.

Changes in the promoter or enhancer sequence that may affect expression levels of *LGR4*, *LGR5* or *LGR7* can be compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer
15 strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β -galactosidase, luciferase, chloramphenicol acetyltransferase, etc., that provides for convenient quantitation; and the like.

A number of methods are available for analyzing nucleic acids for the presence of
20 a specific sequence, e.g. a disease associated polymorphism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express *LGR4*, *LGR5* or *LGR7* may be used as a source of mRNA, which may be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid may be amplified
25 by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki, *et al.* (1985), *Science* 239:487, and a review of techniques may be found in Sambrook, *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2–
14.33. Alternatively, various methods are known in the art that utilize oligonucleotide
30 ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990),

Nucl. Acids Res. **18**:2887-2890; and Delahunty *et al.* (1996), *Am. J. Hum. Genet.* **58**:1239-1246.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, *e.g.* fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, *e.g.* ^{32}P , ^{35}S , ^3H ; *etc.* The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, *etc.* having a high affinity binding partner, *e.g.* avidin, specific antibodies, *etc.*, where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, *e.g.* amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or other methods, and the sequence of bases compared to a wild-type *LGR4*, *LGR5* or *LGR7* sequence. Hybridization with the variant sequence may also be used to determine its presence, by Southern blots, dot blots, *etc.* The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5,445,934, or in WO 95/35505 (the disclosures of which are herein incorporated by reference), may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in *LGR4*, *LGR5* or *LGR7* may be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting

deletions that may affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in LGR4, LGR5 or LGR7 proteins may be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the 5 encoded LGR4, LGR5 or LGR7 protein may be determined by comparison with the wild-type protein.

Antibodies specific for LGR4, LGR5 or LGR7 proteins may be used in staining or in immunoassays. Samples, as used herein, include biological fluids such as semen, blood, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid and the like; organ or tissue 10 culture derived fluids; and fluids extracted from physiological tissues. Also included in the term are derivatives and fractions of such fluids. The cells may be dissociated, in the case of solid tissues, or tissue sections may be analyzed. Alternatively a lysate of the cells may be prepared.

Diagnosis may be performed by a number of methods to determine the absence or 15 presence or altered amounts of normal or abnormal LGR4, LGR5 or LGR7 in patient cells. For example, detection may utilize staining of cells or histological sections, performed in accordance with conventional methods. Cells are permeabilized to stain cytoplasmic molecules. The antibodies of interest are added to the cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least 20 about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other labels for direct detection. Alternatively, a second stage antibody or reagent is used to amplify the signal. Such reagents are well known in the art. For example, the primary antibody may be conjugated to biotin, with horseradish 25 peroxidase-conjugated avidin added as a second stage reagent. Alternatively, the secondary antibody conjugated to a fluorescent compound, *e.g.* fluorescein, rhodamine, Texas red, *etc.* Final detection uses a substrate that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding may be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, *etc.*

30 Diagnostic screening may also be performed for polymorphisms that are genetically linked to a disease predisposition, particularly through the use of microsatellite

markers or single nucleotide polymorphisms. Frequently the microsatellite polymorphism itself is not phenotypically expressed, but is linked to sequences that result in a disease predisposition. However, in some cases the microsatellite sequence itself may affect gene expression. Microsatellite linkage analysis may be performed alone, or in combination 5 with direct detection of polymorphisms, as described above. The use of microsatellite markers for genotyping is well documented. For examples, see Mansfield *et al.* (1994), *Genomics* 24:225-233; Ziegler *et al.* (1992), *Genomics* 14:1026-1031; Dib *et al.*, *supra*.

MODULATION OF *LGR4*, *LGR5* and *LGR7* GENE EXPRESSION

10 The *LGR4*, *LGR5* or *LGR7* genes, gene fragments, or the LGR4, LGR5 or LGR7 protein or protein fragments, are useful in gene therapy to treat disorders associated with *LGR4*, *LGR5* or *LGR7* defects. Expression vectors may be used to introduce the *LGR4*, *LGR5* or *LGR7* gene into a cell. Such vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences. 15 Transcription cassettes may be prepared comprising a transcription initiation region, the target gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, e.g. plasmid; retrovirus, e.g. lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a 20 period of at least about several days to several weeks.

The gene or LGR4, LGR5 or LGR7 protein may be introduced into tissues or host cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth *et al.* (1992), *Anal Biochem* 205:365-368. The DNA may be coated onto gold 25 microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (see, for example, Tang *et al.* (1992), *Nature* 356:152-154), where gold microprojectiles are coated with the *LGR4*, *LGR5* or *LGR7* DNA, then bombarded into skin cells.

Antisense molecules can be used to down-regulate expression of *LGR4*, *LGR5*, or 30 *LGR7* in cells. The anti-sense reagent may be antisense oligonucleotides (ODN), particularly synthetic ODN having chemical modifications from native nucleic acids, or

nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, *e.g.* by reducing the amount of mRNA available for translation, through activation of RNase H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has been found that short oligonucleotides, of from 7 to 8 bases in length, can be strong and selective inhibitors of gene expression (see Wagner *et al.* (1996), *Nature Biotechnol.* 14:840-844).

A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an *in vitro* or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner *et al.* (1993), *supra*, and Milligan *et al.*, *supra*.) Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur;

phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH₂-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamide. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and affinity. The α -anomer of deoxyribose may be used, where the base is inverted with respect to the natural β -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, e.g. 15 ribozymes, anti-sense conjugates, etc. may be used to inhibit gene expression. Ribozymes may be synthesized *in vitro* and administered to the patient, or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (for example, see International patent application WO 9523225, and Beigelman *et al.* (1995), *Nucl. Acids Res.* **23**:4434-42). Examples of oligonucleotides with catalytic activity are 20 described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, e.g. terpyridylCu(II), capable of mediating mRNA hydrolysis are described in Bashkin *et al.* (1995), *Appl. Biochem. Biotechnol.* **54**:43-56.

25 GENETICALLY ALTERED CELL OR ANIMAL MODELS FOR LGR4, LGR5 AND LGR7
FUNCTION

The subject nucleic acids can be used to generate transgenic, non-human animals or site specific gene modifications in cell lines. Transgenic animals may be made through homologous recombination, where the normal *LGR4*, *LGR5* or *LGR7* locus is altered. 30 Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like.

The modified cells or animals are useful in the study of *LGR4*, *LGR5* and/or *LGR7* function and regulation. For example, a series of small deletions and/or substitutions may be made in the host's native *LGR4*, *LGR5* or *LGR7* gene to determine the role of different exons. Of interest is the use of *LGR4*, *LGR5* or *LGR7* to construct transgenic animal models for disease states. Specific constructs of interest include anti-sense *LGR4*, *LGR5* or *LGR7*, which will block *LGR4*, *LGR5* or *LGR7* expression, expression of dominant negative *LGR4*, *LGR5* or *LGR7* mutations, and over-expression of *LGR4*, *LGR5* or *LGR7* genes. Where an *LGR4*, *LGR5* or *LGR7* sequence is introduced, the introduced sequence may be either a complete or partial sequence of an *LGR4*, *LGR5* or *LGR7* gene native to the host, or may be a complete or partial *LGR4*, *LGR5* or *LGR7* sequence that is exogenous to the host animal, e.g., a human *LGR4*, *LGR5* or *LGR7* sequence. A detectable marker, such as *lac Z* may be introduced into the *LGR4*, *LGR5* or *LGR7* locus, where upregulation of *LGR4*, *LGR5* or *LGR7* expression will result in an easily detected change in phenotype.

One may also provide for expression of the *LGR4*, *LGR5* or *LGR7* gene or variants thereof in cells or tissues where it is not normally expressed, at levels not normally present in such cells or tissues, or at abnormal times of development. By providing expression of *LGR4*, *LGR5* or *LGR7* protein in cells in which it is not normally produced, one can induce changes in cell behavior, e.g. through *LGR4*, *LGR5* or *LGR7* mediated activity.

DNA constructs for homologous recombination will comprise at least a portion of the *LGR4*, *LGR5* or *LGR7* gene, which may or may not be native to the species of the host animal, wherein the gene has the desired genetic modification(s), and includes regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown *et al.* (1990), *Meth. Enzymol.* 185:527-537.

For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g. mouse, rat, guinea pig, etc. Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of leukemia

inhibiting factor (LIF). When ES or embryonic cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked
5 and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of
10 pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct. By providing for a different phenotype of the blastocyst and the genetically modified cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the
15 gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in *in vitro* culture. The transgenic animals may be any non-human mammal, such as laboratory animals, domestic animals, etc. The transgenic animals may be used in functional studies, drug screening,
etc., *e.g.* to determine the effect of a candidate drug on *LGR4*, *LGR5* or *LGR7* or related
20 gene activation *etc.*

IN VITRO MODELS FOR LGR4, LGR5 OR LGR7 FUNCTION

The availability of a number of components in the G-protein coupled receptor family, as previously described, allows *in vitro* reconstruction of the processes or systems
25 in which members of this family operate. Two or more of the components, such as the isolated receptor and a potential ligand therefore, may be combined *in vitro*, and the behavior assessed in terms of activation of transcription of specific target sequences; modification of protein components, *e.g.* proteolytic processing, phosphorylation, methylation, *etc.*; ability of different protein components to bind to each other. The
30 components may be modified by sequence deletion, substitution, *etc.* to determine the functional role of specific domains.

Drug screening may be performed using an *in vitro* model, a genetically altered cell or animal, purified LGR4, LGR5 or LGR7 protein, as well as fragments or portions thereof, e.g. solubilized extra-cellular domain or chimeric receptor proteins comprising the LGR4, LGR5 or LGR7 extra-cellular domain. One can identify ligands or substrates that bind to and modulate the action of LGR4, LGR5 or LGR7. Areas of investigation include the development of agents that beneficially counter abnormalities related to LGR4, LGR5 or LGR7 and the use of such agents in the therapy.

Drug screening identifies agents that modulate the activity of LGR4, LGR5 or LGR7 function in abnormal cells. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like. The purified protein may also be used for determination of three-dimensional crystal structure, which can be used for modeling intermolecular interactions, such as GTP binding, etc.

The term "agent" as used herein describes any molecule, e.g. protein or pharmaceutical, with the capability of altering or mimicking the physiological function of LGR4, LGR5 or LGR7. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.

In some embodiments, candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, 5 libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications. 10 such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.

Of particular interest in certain embodiments are peptidic agents based on LGR4, LGR5 or LGR7, e.g. solubilized extra-cellular domain or chimeric receptor proteins comprising the LGR4, LGR5 or LGR7 extra-cellular domain, where such agents 15 neutralize the activity of endogenous LGR4, LGR5 or LGR7 ligands, e.g. hormones.

Where the screening assay is a binding assay, one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemiluminescers, enzymes, specific 20 binding molecules, particles, e.g. magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include 25 reagents like salts, neutral proteins, e.g. albumin, detergents, etc., that are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease 30 inhibitors, anti-microbial agents, etc., may be used. The mixture of components are added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 and 40°C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.

Other assays of interest detect agents that mimic LGR4, LGR5 or LGR7 function. For example, an expression construct comprising an *LGR4*, *LGR5* or *LGR7* gene may be introduced into a cell line under conditions that allow expression. The level of LGR4, LGR5 or LGR7 activity is determined by a functional assay, as previously described. In 5 one screening assay, the ability of candidate agents to inhibit or enhance LGR4, LGR5 or LGR7 function is determined. Alternatively, candidate agents are added to a cell that lacks functional LGR4, LGR5 or LGR7, and screened for the ability to reproduce LGR4, LGR5 or LGR7 activity in a functional assay.

The compounds having the desired pharmacological activity may be administered 10 in a physiologically acceptable carrier to a host for treatment, *etc.* The compounds may also be used to enhance *LGR4*, *LGR5* or *LGR7* function. The inhibitory agents may be administered in a variety of ways, orally, topically, parenterally *e.g.* subcutaneously, intraperitoneally, by viral infection, intravascularly, *etc.* Topical treatments are of particular interest. Depending upon the manner of introduction, the compounds may be 15 formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%.

The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and 20 topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.

25

EXPERIMENTAL

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. 30 Efforts have been made to ensure accuracy with respect to the numbers used (*e.g.* amounts, temperature, concentrations, *etc.*) but some experimental errors and deviations

should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

5 **Example 1. Identification of LGR4 and LGR5**

Human sequences related to the sea anemone and *Drosophila* glycoprotein hormone receptors were identified from the expression sequence tag database (dbEST) at the National Center for Biotechnology Information by using the BLAST server with the BLOSUM62 protein comparison matrix (Altschul SF *et al*, Nucleic Acids Res (1997) 10:3389-3402). Human ESTs showing high homology to two non-overlapping regions of the gonadotropin receptors were identified. Clones AA312798 and AA298810 were found to encode transmembrane four to five of the putative receptor LGR4 whereas AA460529 and AA424098 encode transmembrane two to three of the putative receptor LGR5. Using these ESTs to further search the GenBank EST division database. 15 overlapping EST sequences were aligned to obtain the longest open reading frame (ORF) for these receptors.

Based on the longest human ORF, specific primers were designed for PCR amplification of LGR4 and LGR5 cDNA fragments from rat ovary and human placenta, respectively. After hybridization with labeled EST clones and confirmation of DNA sequences by dideoxy DNA sequencing, specific receptor fragments isolated were used to design primers to prepare sub-cDNA libraries enriched with specific receptor cDNAs. For 20 5' extension, reverse transcription was performed using rat ovarian and human placenta mRNA preparations and receptor-specific primers. Following second strand synthesis, the enriched cDNA pool was tailed at 5'-ends with specific adaptor sequences to allow further 25 PCR amplification. For 3' extension, rat ovarian or human placenta mRNAs were reversed transcribed using oligo-dT, followed by second strand synthesis using receptor-specific primers and adaptor tailing. These mini-libraries were further used as templates for PCR amplification of upstream or downstream cDNAs specific for each receptor using internal primers. PCR products with a strong hybridization signal to each receptor cDNA 30 fragment were subcloned into the pUC18 or pcDNA3 vectors. After screening of these sublibraries based on colony hybridization using specific receptor probes, clones with 5'-

or 3'-sequences of the putative receptors were identified and isolated for DNA sequencing. As needed, the procedure was repeated up to three times to generate cDNAs encoding the complete ORF of each putative receptor for sequence analysis and for the expression of receptor proteins in eukaryotic cells. The entire coding sequences of each gene were also amplified with specific primers flanking the entire ORF in independent experiments. At least three independent PCR clones were sequenced to verify the authenticity of coding sequences. The nucleotide sequence of LGR4, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 1. The nucleotide sequence of LGR5, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 2.

Example 2. Comparison of deduced amino acid sequence of LGR4 and 5 cDNAs and those encoding FSH and LH receptors.

Sequence alignment of LGR4 and LGR5 with known human glycoprotein hormone receptors was performed and the results are shown in Fig. 6. Shaded residues are identical in at least two of the four receptor proteins shown.

Example 3. Expression pattern of LGR4 and 5 mRNA transcripts in different tissues.

For northern blot analysis, poly (A)+-selected RNA from different human tissues was hybridized with a ³²P-labeled cDNA probes. After washing, the blots were exposed to X-ray films at -70C for five days. Subsequent hybridization with a beta-actin cDNA probe was performed to estimate nucleic acid loading (8 h exposure). LGR4 was shown to be expressed in placenta, ovary, testis, adrenal, spinal cord, thyroid, stomach, trachea, heart, pancreas, kidney, prostate and spleen while LGR5 was shown to be expressed in the skeletal muscle, placenta, spinal cord, brain, adrenal, colon, stomach, ovary and bone marrow.

30

Example 4. Chromosomal localization of LGR4 and 5 in human.

Using genomic fragments of LGR4 (>100 Kb) and LGR5 (>100 Kb) as probes, chromosomal localization of these genes were detected using the FISH method to banded DNA in chromosomal 5q34-35.1 and 12q15, respectively.

5

Example 5. Identification of LGR7.

Analysis of EST databases has revealed a novel LGR closely related to a G protein-coupled receptor from pond snail (*Lymnaea stagnalis*, accession no. 481946). Because the snail G-protein coupled receptor shared the leucine-rich repeat ectodomain and seven transmembrane region characteristics of mammalian LGRs, the novel EST sequence could encode either a homologue of snail receptor or a novel mammalian LGR. For the isolation of LGR7 cDNA, a Clontech Marathon-ready testis cDNA pool was used as the template for 5' and 3' RACE with adapter and gene-specific primers. Sequence analysis of the RACE products showed that LGR7 gene encode at least two splicing variants differ at the N-terminus. The nucleotide sequence of the long variant, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 3; while the nucleotide sequence of the short variant, as well as the amino acid sequence of the ORF thereof, is provided in Fig. 4. Both variants contain a classical C-terminal 7-transmembrane region and a leucine-rich repeat ectodomain flanked by cysteine rich regions found in other mammalian LGRs. The long form LGR7 contains extra 35 amino acids in the N-terminal cysteine rich region as compared to the short form LGR7. Of interest, analysis of the LGR7 ORF from either variant showed that its tertiary structure resembles that of mammalian LGRs instead of the snail receptor, which shares the greatest identity in the transmembrane region. These findings suggest that LGR7 and snail receptor diverged early during evolution and LGR7 perhaps adopted new function in higher organisms.

Based on the LGR7 cDNA sequence, we further identified a human genomic DNA fragment (AQ053279) in the genomic survey sequence division of GenBank that contains part of the LGR7 gene. The authenticity of this genomic clone was confirmed by Southern blot hybridization and the genomic clone was used as the probe to identify the chromosomal localization for LGR7 gene.

It is evident from the above discussion and results that three novel mammalian G-protein coupled receptors, as well as a nucleic acids encoding the same, are provided by the subject invention. The inventions described above find use in a variety of applications, including research and therapeutic applications.

5

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The publications discussed herein are provided solely for their disclosure prior to the filing date of the 10 present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such a disclosure by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily 15 apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding a mammalian protein selected from the group consisting of LGR4, LGR5 or LGR7.

5

2. An isolated nucleic acid according to Claim 1, wherein said mammalian protein has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:04, SEQ ID NO:06 or SEQ ID NO:08.

10

3. An isolated nucleic acid according to Claim 1, wherein said mammalian protein has an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:04, SEQ ID NO:06 or SEQ ID NO:08.

15

4. An isolated nucleic acid according to Claim 1, wherein the nucleotide sequence of said nucleic acid has the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

20

5. An isolated nucleic acid comprising at least 18 contiguous nucleotides of the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

25

6. An isolated nucleic acid comprising at least 50 contiguous nucleotides of the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

7. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid having the nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

8. An expression cassette comprising a transcriptional initiation region functional in an expression host, a nucleic acid having a sequence of the isolated nucleic acid according to Claim 1 under the transcriptional regulation of said transcriptional initiation region, and a transcriptional termination region functional in said expression host.

9. A cell comprising an expression cassette according to Claim 8 as part of an extrachromosomal element or integrated into the genome of a host cell as a result of introduction of said expression cassette into said host cell, and the cellular progeny of said host cell.

10. A method for producing a mammalian protein selected from the group consisting of LGR4, LGR5 and LGR7, said method comprising:

growing a cell according to Claim 9, whereby said mammalian protein is expressed; and

isolating said protein substantially free of other proteins.

11. A purified polypeptide composition comprising at least 50 weight % of the protein present as a mammalian protein selected from the group consisting of LGR4, LGR5 and LGR7, or a fragment thereof.

12. An antibody binding specifically to a mammalian protein selected from the group consisting of LGR4, LGR5 and LGR7.

13. The antibody of Claim 12, wherein said antibody is a monoclonal antibody.
14. A non-human transgenic animal model for *LGR4*, *LGR5* or *LGR7* gene function, wherein said transgenic animal comprises an introduced alteration in an *LGR4*,
5 *LGR5* or *LGR7* gene.
15. The animal model of claim 14, wherein said animal is heterozygous for said introduced alteration.
- 10 16. The animal model of claim 14, wherein said animal is homozygous for said introduced alteration.
- 15 17. The animal model of claim 14, wherein said introduced alteration is a knockout of endogenous *LGR4*, *LGR5* or *LGR7* gene expression.
18. A method of screening a sample for the presence of a ligand for a receptor selected from the group consisting of *LGR4*, *LGR5* and *LGR7*, said method comprising:
contacting said sample with a receptor selected from the group consisting of *LGR4*, *LGR5* and *LGR7* or a mimetic thereof, and
20 detecting the presence of a binding event between said receptor and ligand in said sample.

>LGR4 nucleotide sequence (SEQ ID NO.01)

>LGR4 amino acid sequence (SEQ_ID_NO:02)

MPGPLGLLCFLAIGLILGSAGPSGAAPPLCAAFCSCLGDFRVEICGKGTLAVPEGLSAFTQALDISMNNITQLFEDAFKSF
FLEELQLAGNDLSLIHPKALSGKLKELHVITLQNNLRTVPESEAIHGLSALQSLRIDANHITSVPEDSFEGIVQLRHLMDD
NSLTEVTFVPLSNLPTLQALTLALNNISSIFIAFTNLLSSLVVLHLHNMKIKSLSTHCFDGLDNLETLDLNNYNYLDEFFQA
IKALPSLKELGFMHSNSISVIFDGFGBNPLLTIHLHYDNPLSVGNSAFHNLSDLHCLVIRGASLVQWFPMILTGTVHLESI
TILTGTWISSIPDRLCQNQKMLFTLLELSYNNIEFLPSFNGCRALEEISLQFNQISLIKENTFQGLTSLRILLLSRNLIKEJH
SGAFAKI.GTITNLDSFSFNELTSFPTECLNGLNQLKLVGNFKLKDALAARDFANL.SLSVFYAYQCCAFWGCDSLCKLNTEI
NSPQEHSVTKEKGATDAANVTSTAENEELSIIIMCTESTGAFKPCYEYLGSWMIRLTWVFIFIVALLFNLVILTVFASC
SSLFASKLFIGLISVSNLLMGITYTGILTFLAVSWGFAEFGIWWTGSGCKVAGSLAVFSSESAVFLLTLAVERSVPFAK
DLMKHGKSSHLFQFOVAALLALLGAAVAGCFFELFHGGQYSASFCLCPFFTGETPSLGETVTLVLLNSLAFLMMAIIYTCKLY
CNLEKEELSENSISSVIKHVAWLIFTNCIFFCFVAFSFAPLITAISISEIMKSVTLIFISSLPACLNPVLYVFFNPKFKE
EWKLLKFVTRKHGSVSISISQGGCGECDFYYDCGMYSHLQGNLTVCDCCESFLLTKFVSKHLIKCHSCPVLTAASCCR
FEAYWSLQGTQSADEEESFVSISSDQVCAACRACYQSPGFPLVRYAYNLOVED

FIG. 1

>Nucleotide sequence of LGR5 (total 2082 nucleotides) (SEQ ID NO:03)

CTACATCTCCATAACAATAGAACATCCACTCCCTGGAAAGAACATGCTTGATGGGCTCCACAGCCTAGAGACTTTAGATTAA
 ATTACAATAACCTTGTGATGAATTCCCCACTGCAATTAGGACACTCTCAAATTAAAGGAACTAGGATTTCATAGCAACAAAT
 ATCAGGGTCGATAACCTGAGAAAGCATTGTAGGCAACCCCTCTTATTACAATACATTCTATGACAATCCCATCCAATT
 GTTGGGAGATCTGCTTTCAACATTACCTGAACTAAGAACACTGACTCTGAATGGTGCCTCACAAATAACTGAATTTCCT
 GATTAACTGGAACCTGGAGAGTCTGACTTTAAGCTGGAGCACAGATCTCATCTCTCCTCAAACCCTGCAAT
 CAGTTACCTAATCTCAAAGTGTAGATCTGCTTACAACCTATTAGAAGATTACCCAGTTTCTAGTCTGCCAAAAGCTT
 CAGAAAATTGACCTAACAGACATAATGAAATCTACGAAATTAAAGTTGACACTTCCAGCAGTTGCTTAGCCTCGATCGCTG
 AATTGGCTTGGAACAAAATTGCTATTATTACCCCCAATGCATTTCACTTTGCCATCCCTAATAAGCTGGACCTATCG
 TCCAACCTCCTGTCGCTTTCTATAACTGGGTTACATGGTTAACCTAACTTAAACAGGAAATCATGCCCTACAG
 AGCTGGATATCATCTGAAAACCTTCCAGAAACTCAAGGXATAGAAATGCCTTATGCTTACCAAGTGTGCTGTGCATTGGAGTG
 TGTGAGAATGCCTATAAGATTCTAATCAATGGAATAAGGTGACAACAGCAGTATGGACGACCTTCATAAGAAAGATGCT
 GGAATGTTCAAGGCTCAAGATGAACGTGACCTTGAAGATTTCCTGCTTGACTTGAGGAAGACCTGAAAGCCCTTCATTCA
 GTGCAGTGGTACACCTTCCCCAGGCCCTTCAAACCCCTGTAACACCTGCTTGATGGCTGGCTGATCAGAATTGGAGTGTGG
 ACCATAGCAGTCTGGCACTTACTTGTAAATGCTTGGTACTTCAACAGTTTCAAGTCCCCTCTGTACATTCCCCCATT
 AAACCTTAAATTGGGTCACTCGCAGCAGTGAACATGCTCACGGGAGTCTCCAGTGCCTGCTGGCTGGTGTGGATGCGTT
 ACTTTGGCAGCTTGACGACATGGTGCCTGGTGGAGAATGGGTTGGTGCATGTCATTGGTTTTGTCATTTT
 GCTTCAGAACATCTGTTTCTGCTTACTCTGCAGCCCTGGAGCGTGGGTTCTGTGAAATATTCTGCAAATTTGAA
 ACGAAAGCTCCATTCTAGCCTGAAAGTAATCATTGCTCTGCCCCCTGTCGACCATGGCCGCAGTTCCTG
 CTGGGTGGCAGCAAGTATGGCGCCTCCCTCTGCCTGCTTGGCTTTGGGAGGCCAGCACCATGGGCTACATGGTC
 GCTCTCATCTGCTCAATTCCCTTGCTTCTCATGATGACCATTGCTCACACCAAGCTACTGCAATTGGACAAGGG
 GACCTGGAGAATATTGGGACTGCTATGGTAAACACATTGCCCTGTTGCTCTCACCAAGCTCATCTAAACTGCC
 GTGGCTTCTGCTCTCTTAAATAAACCTTACATTATCAGTCTGAAAGTAATTAAAGTTATCCTTCTGGTGGTA
 GTCCCACCTCTGCATGTCTCAATCCCCTCTACATCTGTTCAATCCTCACTTAAAGGAGATCTGGTGGAG
 AAGCAAACCTACGTCTGGACAAGATCAAACACCAAGCTGATGTCATTAACTCTGATGTCGAAAAAACAGTCTGT
 GACTCAACTCAAGCCTGGTAACCTTACCAAGCTCCAGCATCACTTATGACCTGCCCTCCAGTCCGTGCCATCACCAGCT
 TATCCAGTGAAGACTGCCATCTTCTGTCATTGTCCCCATGTCTCTAA

>amino acid sequence of LGR5 (total 693 amino acids) (SEQ ID NO:04)

LHLHNNRIHSLGKKCFDGLHSLETLDLNYYNNLDEFPTAIRTLSNLKELGFHNSNNIRSIPKEKAFVGNPSLITIHFYDNPIQF
 VGRSAFQHLPRLRTLTLNGASQITEFPDLTGTANLESLTGTGAQISSLPQTVCNQLPNLVLDLSYNLLEDLPSFSVCQKL
 QKIDLRHNEIYEIKVDTFQQLLRSLSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLKLTKGNHALQ
 SWISSENPELKVIEMPYAYQCCAFGVCENAVYKISNQWNKGDNSSMDDLHKKDAGMFQAQDERDLEDFLLDFEEDLKLHS
 VQCSPSPGPFPKPCHELLDGWLIRIGWWTIAVLALTCNALVTSTVRSPLYISPIKLLIGVIAAVNMLTVSSAVLAGVD
 TFGSFARHGAWWENGVGCHIVGFLSIFASESSVFLLTLAALERGSVKYSAKFETKAPFSSLKVIIILLCALLALTMAAVPL
 LGGSKYGAAPLCLPLPFGEPMSTMGYVALILLNSLCFLMMTIAYTKLYCNLDKGDELNIWDCMSVKHIALLFTNCILNCP
 VAFLSFSSLINLTFISPEVIKFILLVVVPLPACLNPPLYILFNPHFKEDLVSRLRKQTYVWTRSKHPSLMSINSDDVEKQSC
 DSTQALVFTSSSITYDLPPSSVPSPAYPVTESCHLSSVAFVPL

FIG. 2

>Final LGR7 (LGR7-Long variant) full length sequence (2467 nt) (SEQ ID NO:05).

GAAAGGAGGAAGAAAAAAGAGGAATGGAAAGAGACAGAGAAAGGAATGGGACTTGAAGGAGGGAGGACTGCTTT
 STAAGTCTAACGATTGCAGACAGAAATAGCACACACAACCACGTGAGCTGTATGCAGAACAAAGACCAAAATT
 TTGCTCACTTTCTTAATCAGTTCTCAGATAGAAGGAAATGACATCTGGTTCTGTCTTCTACATCTTAATTT
 TGGAAATATTTCTCATGGGGTGGACAGGATGTCAAGTGCTCCCTGGCTATTCCCCTGGGAACATCACAA
 AGTGCTGCCTCAGCTCCTGCACGTACGGTGTGGACGACTGCAGGAAATCAGGCCATGAGGACAACGTGGAGAC
 AACATGGATGGTCCATGCAATTGACAAATATTGCAAGTTACTACAAAATGACTTCCAATATCCTTGAGGC
 AGAAACACCTGAATGTTGGTCTGTGCCAGTCAATGTCTTGCAAGGTCAGGAGCTGACTGTGATGAAA
 CCAATTACGAGCTGTTCCATGGTTCTTCAAATGTGACTGCAATGTCACTTCAGTGGAACTTAAGAAAGCTT
 CCTCCTGATTGCTCAAGAATTATCATGATCTCAGAACGCTGACCTGCAAAACAAATAAGATTACATCCATCTCCAT
 CTATGCTTCAGAGGACTGAATAGCCTACTAAACTGTATCTCAGTCATAACAGAATAACCTTCTGAAGGCCGGTG
 TTTTGAAAGATCTCACAGACTAGAATGGCTGATAATTGAAGATAATCACCTCAGTCGAATTCCCCACAAACATT
 TATGGACTAAATTCTCTTATTCTTAGTCTGTGATAAACGTCTCACCGTTACCTGATAAAACCTCTGTCA
 ACACATGCCAAGACTACATTGGCTGGACCTGAGGCAACCATATCCATAATTAAAGAAATTGACTTTATTCT
 GCAGTAATTAACTGTTTAGTGTAGAGGAAAACAAAATTAACTAAATGAAATTACTTTGCACCTCTCCAG
 AAACTGGATGAATTGGATTAGGAAGTAATAAGATTGAAAATCTTCCACCGCTTATATTCAAGGACCTGAAGGAGCT
 GTCACAATTGAATCTTCCTATAATCCAATCCAGAAAATTCAAGCAAACCAATTGATTATCTGTCAAACCTCAAGT
 CTCTCAGCCTAGAAGGGATTGAAATTCAAATATCCAACAAAGGATGTTAGACCTTATGAAATCTCTCACATA
 TATTAAAGAAATTCCAGTACTGTGGGTATGCACCATGTCAGCTGAAACCAAACACTGATGGAATTTCATC
 TCTAGAGAATCTCTGGCAAGCATTATTCAAGAGGTATTGTCTGGGTTGTATCTGCAGTTACCTGCTTGAAACAA
 TTTTGTCATTGCAATGCGACCTTATATCAGGTCTGAGAACAGCTGTATGCCATGTCATATTCTCTGTGT
 GCGGACTGCTTAATGGGAAATATTTATTCTGTGATGGAGGCTTGCACCTAAAGTTCTGTGGAGAATAACAATAAGCA
 TGCAGCTGTGGATGGAGAGTACTCATTGTCAGCTGTAGGATCTTGGCATTCTGTCACAGAAAGTATCAGTT
 TACTTTAAACATTCTGACATTGAAAATACATCTGATTGTCTTATGGTTTATAGTGGCTTCATTCCATTGAGCAATAAGGAAATT
 AGAACAAATTACAGTTCTGATTCATTTGGATTACTGGTTTATAGTGGCTTCATTCCATTGAGCAATAAGGAAATT
 TTTCAAAAATCTATGGCACCAATGGAGTATGCTCCCTCTTCATTCAAGAATACAGAAAGTATTGGAGGCCCAGA
 TTTATTCACTGGCAATTCTTCTGGTATTAATTGGCGCATTATCATCATAGTTTCTCTATGGAAGCATGTT
 TATAGTGTTCATCAAAGTGCATAACAGCAACTGAAATCAGGAATCAAGTTAAAAGAGATGATCCTTGCAAACCG
 TTTTTCTTATAGTATTCTGATGCATTATGCTGGATACCCATTGGTAGTGAATTCTTCATTGCTTCAGG
 TAGAAATACCAAGGTACCATACCTCTGGTAGTGTATTATTCTGCCATTAAACAGTGTCTGAACCCATTCT
 TATACTCTGACCACAAGACCATTAAAGAAATGATTCATCGGTTTGGTATAACTACAGACAAAGAAAATCTATGGA
 CAGCAAAGTCAGAAAACATATGCTCCATCATTCACTGGTGGAAATGTGGCACTGCAGGAGATGCCACCTGAGT
 TAATGAAGCGGACCTTTCACATACCCCTGTGAAATGTCACTGATTCTCAATCACGAGACTCAATTCTATTCA
 TGA

>Final LGR7 (LGR7-long variant, total 757 amino acids)(SEQ ID NO:06)

MTSGSVFFYILIFGKYFSHGGGQDVCKSLGYFPCGNITKCLPQLLHCNGVDCGNQADEDNCGDNNNGWSMQFDKYFA
 SYYKNTSQYPFEAEPECLVGSPVQCLCQGLELDCDETNLRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLOK
 LYLNQNIKTSISIYAFRGLNSLTKLYLSHNRIFLKPGVFEDLHRLEWLIIEDNHLRSRISPPFTYGLNSLILLVLMN
 NVLTRLPDKPLCQHMPRLHWLDLEGNHINLRLNTFICCSNLTVLVMRKNKINHLNENTFAPLQKLDELDLGSNKIE
 NLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLLEGIEISNIQQRMFRPLMNLSHIYFKKFQYCGYAPH
 VRSCKPNTDGSSLNLASIIRQVFVWVVAUTCFGNIIFVICMRPYIRSENLYAMSIIISLCCADCLMGYIYLFIG
 GFDLKFRGEYNKHAQLWMESTHCQLVGSLAILSTEVSVLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWTG
 FIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAIFIIVFSYGSMFYSVHQSAITATEI
 RNQVKKEMILAKFFFIVFTDALCWIPIFIYVVKFLSLLQVEIPGTITSWVVIIFLPINSALNPILYTLTRPFKEMIH
 RFWNYRQRKSMDSKGQKTYAPSFIWVEMPLQEMPPLEMKPDLFTYPEMSLISQSTRLNSYS*

FIG. 3

Final LGR7 (LGR7-Short variant) full length sequence (3584 nt)(SEQ ID NO:07)

>Final LGR7-S ORF (722 amino acids) (SEQ ID NO:08)

MTSGSUVFFYILIFGKYFSHGGQDVKCSLGYPFCGNITKCLPOLLHCNGVDDCGNQADEDNCVVVLQCMSLPGLEL
DWMKPFTSVPSVSSNTAMSILQWNLIRKLPPDCFKNYHDLQKLDLQNNKITSISIYAFRGLNSLTKLYLSHNRITFL
KPGVFEDLHRLEWLIEDNHLSRISPPTFYGLNSLILLVLMNNJVLTRLPDKPLCQHMPRLHWLDLEGNHHNLRLNLT
FISCSENLTIVMRKNKINHLNENTFAPLOKLDDELGI.GSNKIEJI.PPI.TFKDI.KELSQLNLSYNPIOKIOANOFDYLV
KLKSLSLLEGIEISNIQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCPNTDGIISSLNLLASIIRQVFJWVSAVTC
FGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFGVIGGFDLKFRGEYNAHAQLWMESTHCQLVGSLAILSTE
VSVLLLTFLTLEKYICIVYPFRVCVRPGKCRTITVLILIWTGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESI
GAQIYSWAIFLGINLAIFIIVFSYGSMFYSVHQSAITATEIRNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLS
LLQVEIPSTITSWVVIIFLPINSALNPILYTLTTRPFKEMIHRFWYNYQRKSMDSKQKTYAPSFIWWEMWPLQEM
PPLEMKEDLFYTPECEMSLISOSTRLNSYS*

FIG. 4

5/8

>Alignment of LGR7-L with LGR7-S

Query=LGR7-L**Sbjct=LGR7-S**

Query: 1 MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADED 60
 MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADED
 Sbjct: 1 MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADED 60

Query: 61 NCGDNNGWMSMQFDKYFASYYKMTSQYPFEAETPECLVGSVPVQCLCQ---GLELD CDETN 117
 NC V V C C GLELD +
 Sbjct: 61 NC-----VVVLQCQCMSPGLELDWMKP- 82

Query: 118 LRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLYLQNNKITSISIYAFRGLNSLT 177
 +VPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLYLQNNKITSISIYAFRGLNSLT
 Sbjct: 83 FTSVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLDLQNNKITSISIYAFRGLNSLT 142

Query: 178 KLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRL 237
 KLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRL
 Sbjct: 143 KLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRL 202

Query: 238 PDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCNLTVLVMRKKNKINHLNENTFAPLQKL 297
 PDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCNLTVLVMRKKNKINHLNENTFAPLQKL
 Sbjct: 203 PDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCNLTVLVMRKKNKINHLNENTFAPLQKL 262

Query: 298 DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLLEGIEISN 357
 DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLLEGIEISN
 Sbjct: 263 DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLLEGIEISN 322

Query: 358 IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCPNTDGISSLENLLASIIQRVFVWWVSA 417
 IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCPNTDGISSLENLLASIIQRVFVWWVSA
 Sbjct: 323 IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCPNTDGISSLENLLASIIQRVFVWWVSA 382

Query: 418 VTCFGNIFVICMRPYIRSENKLYAMSIISLCADCLMGIFYLFVIGGFDLKFRGEYNKHAQ 477
 VTCFGNIFVICMRPYIRSENKLYAMSIISLCADCLMGIFYLFVIGGFDLKFRGEYNKHAQ
 Sbjct: 383 VTCFGNIFVICMRPYIRSENKLYAMSIISLCADCLMGIFYLFVIGGFDLKFRGEYNKHAQ 442

Query: 478 LWMESTHQLVGLAILSTEVSVLLTFLTLEYIICIVYPFRCPKGCRITITVLILIWI 537
 LWMESTHQLVGLAILSTEVSVLLTFLTLEYIICIVYPFRCPKGCRITITVLILIWI
 Sbjct: 443 LWMESTHQLVGLAILSTEVSVLLTFLTLEYIICIVYPFRCPKGCRITITVLILIWI 502

Query: 538 TGFIVAFIPLSNKEFFKNYYGTNGVCPLHSEDTESIGAQIYSVAIFLGINLAIFIIVF 597
 TGFIVAFIPLSNKEFFKNYYGTNGVCPLHSEDTESIGAQIYSVAIFLGINLAIFIIVF
 Sbjct: 503 TGFIVAFIPLSNKEFFKNYYGTNGVCPLHSEDTESIGAQIYSVAIFLGINLAIFIIVF 562

Query: 598 SYGSMFYSVHQSAITATEIRNQVKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEI 657
 SYGSMFYSVHQSAITATEIRNQVKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEI
 Sbjct: 563 SYGSMFYSVHQSAITATEIRNQVKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEI 622

Query: 658 PGTITSWVVFILPINSALNPILYTLTRPFKEMIHRFWYNRQRKSMDSKGQKTYAPSF 717
 PGTITSWVVFILPINSALNPILYTLTRPFKEMIHRFWYNRQRKSMDSKGQKTYAPSF
 Sbjct: 623 PGTITSWVVFILPINSALNPILYTLTRPFKEMIHRFWYNRQRKSMDSKGQKTYAPSF 682

Query: 718 IWVEMWPLQEMPPPELMKPDLFTYPCEMSLISQSTRLNSYS 757
 IWVEMWPLQEMPPPELMKPDLFTYPCEMSLISQSTRLNSYS
 Sbjct: 683 IWVEMWPLQEMPPPELMKPDLFTYPCEMSLISQSTRLNSYS 722

FIG. 5

6.8

FIG. 6

Signal peptide

LGR4	MPGPLGLL CFLALG LLLGSAGPSGA
LGR5	M DTSRLGVLLSIPVLLQLATG
LHR	M KQRF S AQLLLKLLL QPPL PRA
FSHR	M ALLLV SLLAFLS LGSG
TSHR	M RPA D L L Q L V L L D L P R D L G G

N-flank cysteine-rich sequence

LGR4	APPL	AA-P	S	DGDR---	RVD	SGKGLTAVPEGLSAFTQAA
LGR5	GSSPRSGVLLRG	P-TH	H	EPDGRMLLRVD	SDLGLSELPNSNLSVFTSY	
LHR	LREAL	P-EP	N	VPDG--ALR--	PGPTAGLTR	
FSHR		HHRI	H	SNRVFL-----	QESKVTEIPSDLPRNAIE	
TSHR	MG	SSPP	E	HQEED--FRVT	KDIQIRIPSLLPPSTOT	

Leucine-rich repeats

LGR4 DISMNNITQLPED KSFPFLEELQLAGN -- SL HPKALSG KE KVLTLOQ - Q
 LGR5 DLSMNNISQLLPNPLPSLHFLEELRLAGNA-- TY PKGA TG YS KVLMLO - Q
 LHR SLAYLPVKVIPSQ RGLNEVIKIEISQI S- ER EANA DN LN SEILIQ TK -
 FSHR RFVLTKLRLVIQKG SGFGDLEKIEISQN V- EV EADV SN PK HEIRIEKAN -
 TSHR KLIETHLRTIPSH SNLPNISRIYVSI- VT QQLESHS YN SKVTHIEIR TR -

LGR4 RTV- SE IHG SA QS RLDA H- TSV EDS--FEGLVQLRH WLD S-L- EV VR
 LGR5 RVH- TE LQN RS QS RLDA H- SYV P-SC-FSGLHSLRH WLD A-L- E VQ
 LHR RYIE -G FIN PG KY SIC- TG RKF DVTKVFSSESNF- EIC LHI- T GNI
 FSHR LYIN -E FQN PN QY LIS- TG KHL DVHK-IHSLQKV- DIQ INIH - ERN
 TSHR TYID -D LKE PL KF GIF- TGLKMF DLTK-VYSTDIFFI EIT PYM- S VN

LGR4 PLSN P-TLQA T AL NISSIPDF T LSS VV H HN K-IKSLSQHC D LDN-LE
 LGR5 A RS S-ALQAMT AL KIIHIPDY G LSSWVV H HN R-IHSLGKKC D LHS-LE
 LHR A QGMNNESVT K YG GFEEVQSH - GTT TS E KE VHLEKMHNGA R A-TGPK
 FSHR S VG SFESVI W NK GIQEIHNC - GTQ DE N SD NNLEELPNDV H A-SGPV
 TSHR A QG CNETLT K YN GFTSVQGY - GTK DAVY NK KYLTVIDKDA G VYSGPS

LGR4 T LNYNYLDEF Q-AIKA PS KELGFHSNSISVI D-GA GGNPL RTIH - DNPLS
 LGR5 T LNYNNLDEF T-AIRT SN KELGFHSNNIRSI E-KA VGNPS ITIHF- DNPIQ
 LHR T ISSTKLQAL SYGLESIQR I-ATS-SYSLKKL SRET V-N-- LEAT T ----
 FSHR I ISRTRIHSY SYGLEN KK R-ARSTYN-LKKL TLEKLVA--- MEAS T ----
 TSHR L VSQTSVTAL SKGLEH KE I-ARNTWT-LKKL LSLS LH--- TRAD S ----

LGR4 FVGNSAFHNLSDLHCLVIRGASLVQWFPNLTGTGVHLESLTGTCKISSIPDDLCQNQKML
 LGR5 FVGRSAFQHLPPELRTLTLNGASQITEFPDLTGTANLESLTGTGAQISSLPQTVCNQLPML
 LHR
 FSHR
 TSHR

7 / 8

LGR4 RTLDLSYNNIIRDLPFNGCRALEEISLQRNQISLIKENTFQQLTLSRILDLRSRNLI
 LGR5 QVLDLSYNLLLEDLPSFSVCQKLQKIDLRHNEIYEIKVDTFQQLLRLSLNLAWNKIAIIH
 LHR -----
 FSHR -----
 TSHR -----

LGR4 SGAFAKLGTITNLDVSFNELTSFPTEGLNGLNQLK
 LGR5 PNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLK
 LHR -----
 FSHR -----
 TSHR -----

C-flank cysteine-rich sequence

LGR4 LVGNFKLKDALAARDFANLRSLSV YAYQ WGCDSLCKLNTEEDNSPQEHSVTK
 LGR5 LTGNHALQSLISSENFPPELKVIEM YAYQ GVCENAYKISNQWNKGDNSSMDDLHKK
 LHR ----- --SH RNLPTKEQNFSHSISENFSKQC
 FSHR ----- --SH ANWRRQISELHPICNKSI
 TSHR ----- --SH KNQKKIRGILES
 MCNESSMQSLRQK

LGR4 TDAANVTSTAENE HS-----
 LGR5 DAGMFQAQDERDL DF-----
 LHR KVSNKTLYSSMLA SE-----
 FSHR QTRGQRSSLAEVN SS-----
 TSHR SVNALNSPLHQEY ENLGDSIVGYKEKS
 KFDTHNNAHYYVFFEEQEDEIIGFGQELKNP

LGR4 ----- QIIIH T STGA K YLLGSWMI
 LGR5 ----- LLDFEEDLKAHLHSVQ S SPGP K HLLDGWLI
 LHR ----- LSGWDYEFYGFCLPKTPR- A EPDA N DIMGYDFL
 FSHR YSRGFDMTYTEFDYDLCNEVVDVT S KPDA N DIMGYNIL
 TSHR QEETLQAFDSHYDYTICGDSEDMV T KSDE N DIMGYKFL

Transmembrane**TM 1****TM 2**

LGR4 LTV F FLV LLF LL ILTVAFA CSS PASKLFIGLISVSNLLM IYTGILTFL AVSW
 LGR5 IGV T AV LTC AL TSTVFR PLYISPIKL IGVIAAVNMLT VSSAVL G AF F
 LHR VLI L NI IMG MT LFVLLT RYK TVPRF MCNLSFADFCM LYLLLI S SQ K
 FSHR VLI F SI ITG II LVILTT QYK TVPRF MCNLAFADLCI IYLLLI S IH K
 TSHR IVV FVSL LLG VF LLILLT HYK NVPRF MCNLAFADFCM MYLLLI S LY H

TM 3

LGR4 GRFAEFG W E S KV SLA S SA FL LAAV SVFAKDLMKHGKSSH QF
 LGR5 GSFARHGAW EN V HVI LSI S FL LAA GFSVKYSAKFET APFSSL
 LHR GQYYNHA D Q S ST FT L YT VIT WHTITYAIHLDQ LR HA
 FSHR SQYHNYA D Q A DA FT L YT AIT WHTITHAMQLDC VQ HA
 TSHR SEYYNHA D Q P NT FT L YT VIT WYAITFAMRLDR IR HA

FIG. 6 (CONT)

S S

TM 4

LGR4	QVAALLALLGAAVAGOF	FHGGQ SASPL	FPTGETPSLGFTNTLVL	SL LLMA
LGR5	KVIILLCALLALTM AV	L G K GASPL	LPFGEPMSTMG MVALIL	SLC LMMT
LHR	ILIMLGGWLFSSLI ML	V V N MKVSI F	MDVETTLSQV ILTILI	W FIIC
FSHR	ASVMVMGWFIAFAA LF IF I S MKVSI	MDIDSPSQL VMSSLV	VL VVIC	
TSHR	CAIMVGGWVCCFL L	V I S AKVSI	MDTETPLALA IVFVLT	IV VIVC

TM 5

LGR4	II T L CNL-EKEDLENSQSSVI	HV W	NCIFFC VA FSFAPLITAIS SPEI
LGR5	IA T L CNL-DKGDLERI CSMV HI L L		NCILNC VA LSF SLINLTF SPEV
LHR	AC I I FAVRNPELMATNK TKIA KM I		DFTCMA IS FAI AAFKVPL TVTN
FSHR	GC IHI LTVRNPNISSSS TRIA RM M		DFLCMA IS FAI ASLKVPV TVSK
TSHR	CCHV I ITVRNPQYNPGDK TKIA RM V		DFICMA IS YAL AILNKPL TVSN

TM 7

LGR4	M SVTLI F LPA L	V VF N	
LGR5	I FI LVVV LPA L	L IL N	
LHR	S VL VL Y INS A	F AI T	
FSHR	A IL VL H INS A	F AI T	
TSHR	S IL VL Y LNS A	F AI T	

C-terminal tail

LGR4	PK KE WKL KRRVTRKHGSVSVSISSEQGGCGEQDFYYDCGMYSHLQGNLTVCDCCESFL	
LGR5	PH KE LVS RKQTYVWTRSKHPSLMSINSDDVEKQSCDSTQALVTFTSSSITYDLPPSS	
LHR	KT QR FFL LSKFGCCKRAELYRRKDFSAYTSNCKNGFTGSNPKSQSTLKLSTLHCQG	
FSHR	KN RR FFI LSKCGCYEMQAQIYRTETSSTVHNTHPRNGHCSSAPRVTVNGSTYILVPLS	
TSHR	KA QR VFI LSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELI	
LGR4	LTKPVSKHLIKSHCPVLTAAASCQREAYWSDCGTQS AHDYADEEDSFVSDSSDQVQA	
LGR5	VPSPAYPVTESCHLSSVAFVPCL	
LHR	TALLDKTRYTEC	
FSHR	HLAQN	
TSHR	ENSHLTPKKQGQISEEYMQTVL	
LGR4	CGRACFYQSRGFPLVRYAYNLQRVRD	

FIG. 6 (CONT)

SEQUENCE LISTING

<110> Liu, Aaron
 Hsu, Yu Sheau
 Liang, Shan-Guang
 van der Spek, Petrus Johannes

<120> Novel Mammalian G-Protein Coupled
 Receptors Having Extracellular Leucine Rich Repeat Regions

<130> SUN-84PCT

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2856

<212> DNA

<213> human

<400> 1

atgcggggcc	cgttagggct	gctctgccttc	ctcgccctgg	ggctgctcgg	ctcgccgggg	60
cccaggggg	cgggccggcc	tctctgcgcg	gcgcctgtca	gctgcgcacgg	cgaccgtcgg	120
gtggactgt	ccggaaaggg	gttgacggcc	gtacccggagg	gtctcagcgc	cttcacccaa	180
gcactggata	tcagtagaa	caatatacacc	cagtttaccag	aagatgcatt	taagagtttc	240
ccatTTtag	aggagctaca	actggctgtt	aacgaccttt	ctcttatcca	tccaaaagcc	300
ttgtctgggc	tgaaaagaact	caaagtctta	acactccaga	ataatcaatt	gagaacagtg	360
cccagtgaag	ccattcacgg	actgagtgct	ttgcagttt	tacgcttaga	tgccaaaccat	420
attaccttag	tcgggagga	cagttttgaa	gggcttgc	agttacgcca	tctgtggctg	480
gatgacaaca	gcgtgacgga	agtgcggcgt	cgtccccctca	gcaacctgccc	aaccctgcag	540
gcgcgtgaccc	tggcictcaa	caacatctca	agcatccctg	acttcgtttt	caccAACCTT	600
tcaagcttgg	tggttctgca	tctgcataaac	aataaaaattt	aaagcctcag	tcaacactgt	660
tttgcgttgg	tagataaccc	ggaaaccttg	qacttgaatt	acaattactt	ggatgagttt	720
cctcaggctt	ttaaagccct	tcccagccctt	aaagagctgg	gatttcacag	taattctatt	780
tctgttattt	ctgatggagc	atttgggtgtt	aatccactqc	taqaactat	tcatttgtat	840
gataateccc	tgtctttgtt	ggggaaactca	gcattttcaca	acotgtctga	tctgcattqc	900
tttgttattt	ctgggtcaag	cctgggtcag	ttgttccca	atctgacccg	aactgtccat	960
ttggagagtc	taaccttgac	agggacaaaa	ataaagcagca	tacctgtatga	tctgtgccaa	1020
aacccaaaaga	tgcgtaggac	tctggactta	tcttataaca	atataaagaga	ccttccaagt	1080
ttaatgggtt	gtcgtgcatt	gaaagaaaattt	tcatgtcagc	gtaatcaaatt	ctccctaata	1140
aaggaaaata	cttttcaagg	cctaacaatct	ctaaggattt	tagatctgag	tagaaaacctg	1200
atccgtgaaa	tccacagtgg	agcttttgcg	aagcttggga	caattactaa	cctggatgtta	1260
agtttcaatg	aattaacttc	atttcctacg	gaaggcctaa	atgggctcaa	tcaactaaag	1320
cttgcgggtt	acttcaagct	gaaagacgcc	ttggcagcca	gagactttgc	taatctcagg	1380
tctctatcag	taccatatgt	ttatcagttt	tgtgcatttt	gggggtgtga	ctctttatgc	1440
aaattaaaca	cagaagataa	cagcccccaa	gaacacagtg	tgacaaaaaga	gaaaggtgtt	1500
acagatgcag	caaagtctca	cagcactgtt	gagaacgaag	aacatacgca	aataattatc	1560
cactgtacac	cttcaacagg	tgctttcaag	ccctgtgaat	atttactggg	aagotggatg	1620
attgccttia	cagtgtggtt	cattttctgt	gtcgcttgc	ttttcaactt	getttgtcatt	1680
ttaacagttt	ttgcgttctt	ttcatcactg	cctgccttca	aacttttcat	aggcttgatt	1740
tctgtgtata	acttactcat	gggcatttat	actggcatcc	ttacttttct	tgatgtgtt	1800
tcttggggcc	gatTTGCCGA	atTTGGCATT	TGGTGGAAA	CTGGCAGCGG	CTGCAAGGTA	1860
gccgggtctc	tggcagtctt	ctccctcaag	agcgjtgat	tcattttac	actggcagct	1920
gtggaaagaa	gggttatttgc	aaaggatttt	atqaaacacg	ggaagagcag	tcacccaga	1980
cagttccagg	tggccgcctt	cttagctttt	ctgggtgcgg	cagtggcagg	ctgcgttccc	2040
ctttccacag	gagggcaata	ttctgcattc	cccttgcgtt	tgccgttccc	tacaggagaa	2100

210

- 211 - 951

4-212 > PRT

2.1.3. human

- 4 (00) - 2

Met	Phe	Gly	Phe	Ileu	Gly	Ileu	Gly	Ileu	Cys	Phe	Ileu	Ala	Ileu	Gly	Ileu	Ileu
1									10							18
Sly	Ser	Ala	Gly	Pro	Ser	Gly	Ala	Ala	Pro	Pro	Ileu	Cys	Ala	Ala	Pro	
									20			25			30	
Cys	Ser	Cys	Asp	Gly	Asp	Arg	Arg	Val	Asp	Cys	Ser	Gly	Ilys	Gly	Ileu	
									35			40			45	
Thr	Ala	Val	Irc	Gly	Ileu	Ser	Ala	Phe	Thr	Gln	Ala	Ileu	Asp	Ile		
									50			55			60	
Ser	Met	Asn	Asn	Ile	Thr	Gln	Ileu	Pro	Glu	Asp	Ala	Phe	Lys	Ser	Phe	
									65			70			75	
Pro	Phe	Ileu	Gly	Glu	Ileu	Gln	Ileu	Ala	Gly	Asn	Asp	Ileu	Ser	Ileu	Ile	
									85			90			95	
His	Pro	Lys	Ala	Ileu	Ser	Gly	Ileu	Lys	Gly	Ileu	Lys	Val	Ileu	Thr	Ileu	
									100			105			110	
Gln	Asn	Asn	Gln	Ileu	Arg	Thr	Val	Pro	Ser	Gly	Ala	Ile	His	Gly	Ileu	
									115			120			125	
Ser	Ala	Ileu	Gln	Ser	Ileu	Arg	Ileu	Asp	Ala	Asn	His	Ile	Thr	Ser	Val	
									130			135			140	
Irc	Gly	Asp	Ser	Phe	Gly	Ileu	Val	Gln	Ileu	Arg	Ileu	Trp	Ileu			
									145			150			160	
Asp	Asp	Asn	Ser	Ileu	Thr	Gln	Val	Pro	Val	Arg	Irc	Ileu	Ser	Asn	Ileu	
									165			170			175	
Irc	Thr	Ileu	Gln	Ala	Ileu	Thr	Ileu	Ala	Ileu	Asn	Asn	Ile	Ser	Ser	Ile	
									180			185			190	
Pro	Asp	Phe	Ala	Phe	Thr	Asn	Ileu	Ser	Ser	Ileu	Val	Val	Ileu	His	Ileu	
									195			200			205	
His	Asn	Asn	Lys	Ile	Ilys	Ser	Ileu	Ser	Gln	His	Cys	Phe	Asp	Gly	Ileu	
									210			215			220	
Asp	Asn	Ileu	Glu	Thr	Ileu	Asp	Ileu	Asn	Tyr	Asn	Tyr	Ileu	Asp	Glu	Phe	
									225			230			235	
Irc	Gln	Ala	Ile	Ilys	Ala	Ileu	Pro	Ser	Ileu	Ilys	Glu	Ileu	Gly	Phe	His	
									245			250			255	
Ser	Asn	Ser	Ile	Ser	Val	Ile	Irc	Asp	Gly	Ala	Phe	Gly	Gly	Asn	Pro	
									260			265			270	
Ileu	Ileu	Arg	Thr	Ile	His	Ileu	Tyr	Asp	Asn	Pro	Ileu	Ser	Phe	Val	Gly	
									275			280			285	
Asn	Ser	Ala	Phe	His	Asn	Ileu	Ser	Asp	Ileu	His	Cys	Ileu	Val	Ile	Arg	
									290			295			300	

Gly Ala Ser Ileu Val Gin Trp Phe Pro Asn Ile Thr Val Val His
 305 310 315 320
 Leu Gln Ser Leu Thr Ile Thr Gly Thr Lys Ile Ser Ser Ile Pro Asp
 325 330 335
 Asp Leu Cys Gln Asn Gln Lys Met Leu Arg Thr Ile Asp Leu Ser Tyr
 340 345 350
 Asn Asn Ile Arg Asp Leu Pro Ser Phe Asn Gly Cys Arg Ala Leu Glu
 355 360 365
 Glu Ile Ser Leu Gln Arg Asn Gin Ile Ser Leu Ile Lys Glu Asn Thr
 370 375 380
 Phe Gin Gly Leu Thr Ser Leu Arg Ile Leu Asp Leu Ser Arg Asn Leu
 385 390 395 400
 Ile Arg Glu Ile His Ser Gly Ala Phe Ala Lys Leu Gly Thr Ile Thr
 405 410 415
 Asn Leu Asp Val Ser Phe Asn Glu Leu Thr Ser Phe Pro Thr Glu Gly
 420 425 430
 Leu Asn Gly Leu Asn Gln Leu Lys Leu Val Gly Asn Phe Lys Leu Lys
 435 440 445
 Asp Ala Leu Ala Ala Arg Asp Phe Ala Asn Leu Arg Ser Leu Ser Val
 450 455 460
 Phe Tyr Ala Tyr Gin Cys Cys Ala Phe Trp Gly Cys Asp Ser Leu Cys
 465 470 475 480
 Lys Leu Asn Thr Glu Asp Asn Ser Pro Gin Glu His Ser Val Thr Lys
 485 490 495
 Glu Lys Gly Ala Thr Asp Ala Ala Asn Val Thr Ser Thr Ala Glu Asn
 500 505 510
 Glu Glu His Ser Gin Ile Ile His Cys Thr Pro Ser Thr Gly Ala
 515 520 525
 Phe Lys Pro Cys Glu Tyr Leu Leu Gly Ser Trp Met Ile Arg Leu Thr
 530 535 540
 Val Trp Phe Ile Phe Leu Val Ala Leu Phe Asn Leu Leu Val Ile
 545 550 555 560
 Leu Thr Val Phe Ala Ser Cys Ser Ser Leu Pro Ala Ser Lys Leu Phe
 565 570 575
 Ile Gly Leu Ile Ser Val Ser Asn Leu Leu Met Gly Ile Tyr Thr Gly
 580 585 590
 Ile Leu Thr Phe Leu Asp Ala Val Ser Trp Gly Arg Phe Ala Glu Phe
 595 600 605
 Gly Ile Trp Trp Glu Thr Gly Ser Gly Cys Lys Val Ala Gly Ser Leu
 610 615 620
 Ala Val Phe Ser Ser Glu Ser Ala Val Phe Leu Leu Thr Leu Ala Ala
 625 630 635 640
 Val Glu Arg Ser Val Phe Ala Lys Asp Leu Met Lys His Gly Lys Ser
 645 650 655
 Ser His Leu Arg Gin Phe Gin Val Ala Ala Leu Leu Ala Leu Gly
 660 665 670
 Ala Ala Val Ala Gly Cys Phe Pro Leu Phe His Gly Gly Gln Tyr Ser
 675 680 685
 Ala Ser Pro Leu Cys Leu Pro Phe Pro Thr Gly Glu Thr Pro Ser Leu
 690 695 700
 Gly Phe Thr Val Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu
 705 710 715 720
 Met Ala Ile Ile Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp
 725 730 735
 Leu Ser Glu Asn Ser Gln Ser Ser Val Ile Lys His Val Ala Trp Leu
 740 745 750
 Ile Phe Thr Asn Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe
 755 760 765

Asn Ile Val Pro Ala Ile Ser Pro Asp Ile Ser	815	Met Lys Ser
Val Thr Leu Ile Thr His Ile Leu Ile Ala Asp Leu Asn Ile Val Leu	816	
Lys Val Ile Ile Asn Asp Lys Ile Ile Asp Ile Ile Lys Leu Leu Lys	817	
Arg Asp Val Thr Arg Lys His Gly Ser Val Ser Val Phe Ile Ser Ser	818	
	819	
Gln Gly Gly Cys Gly Glu Glu Asp Phe Tyr Tyr Asp Cys Gly Met Tyr	820	
	821	
Ser His Leu Gln Gly Asn Leu Thr Val Cys Asp Cys Cys Glu Ser Phe	822	
	823	
Leu Leu Thr Lys Pro Val Ser Cys Lys His Leu Ile Lys Ser His Ser	824	
	825	
Cys Pro Val Leu Thr Ala Ala Ser Cys Gln Arg Pro Glu Ala Tyr Trp	826	
	827	
Ser Asp Cys Gly Thr Gln Ser Ala His Ser Asp Tyr Ala Asp Glu Glu	828	
	829	
Asp Ile Thr Val Ser Asp Ser Ser Asp Gln Val Glu Ala Cys Gly Arg	830	
	831	
Ala Asp Phe Tyr Gln Ser Arg Gly Phe Pro Leu Val Arg Tyr Ala Tyr	832	
	833	
Asn Ile Gln Arg Val Arg Asp	834	
	835	
Asp Ile Gln Arg Val Arg Asp	836	
	837	

111-3
111-2082
111-DNA
111-human

4. CONC

ttttccatcc taaaatcgcc tctggcttcc ttatcccttc cctttttat aaacccraca	1740
tttattcagtc ctcaggataat taadtttata ctcttgcgtg tagtcccact tccttcatgt	1800
ctcaatcccc ttctctacat ctgttcaat ccttacttta aggaggatct cgtgagccs	1860
agaaaacaaa ctacgtctg qacaadaica aaacacccaa ctttgatgtc aattaactct	1920
catgtatgtcg aaaaacacgtc ctgtgactca actcaagctt tggtaacctt taccagctcc	1980
agccatcactt atgacctgac tcccaactcc gipccatcac cagcttaccc agtcaactqag	2040
agctgccatc ttctctctgt ggcatttata ccatctctct aa	2082

<210> 4

<211> 693

<212> PRT

<213> Human

<400> 4

Leu His Leu His Asn Asn Arg Ile His Ser Leu Gly Lys Lys Cys Phe	
1 5 10 15	
Asp Gly Leu His Ser Leu Glu Thr Leu Asp Leu Asn Tyr Asn Asn Leu	
20 25 30	
Asp Glu Phe Pro Thr Ala Ile Arg Thr Leu Ser Asn Leu Lys Glu Leu	
35 40 45	
Gly Phe His Ser Asn Asn Ile Arg Ser Ile Pro Glu Lys Ala Phe Val	
50 55 60	
Gly Asn Prc Ser Leu Ile Thr Ile His Phe Tyr Asp Asn Pro Ile Gln	
65 70 75 80	
Phe Val Gly Arg Ser Ala Phe Gin His Leu Pro Glu Leu Arg Thr Leu	
85 90 95	
Thr Leu Asn Gly Ala Ser Gln Ile Thr Glu Phe Pro Asp Leu Thr Gly	
100 105 110	
Thr Ala Asn Leu Glu Ser Leu Thr Leu Thr Gly Ala Gln Ile Ser Ser	
115 120 125	
Leu Prc Gln Thr Val Cys Asn Gln Leu Pro Asn Leu Gln Val Leu Asp	
130 135 140	
Leu Ser Tyr Asn Leu Leu Glu Asp Leu Pro Ser Phe Ser Val Cys Gln	
145 150 155 160	
Lys Leu Gln Lys Ile Asp Leu Arg His Asn Glu Ile Tyr Glu Ile Lys	
165 170 175	
Val Asp Thr Phe Gln Gln Leu Leu Ser Leu Arg Ser Leu Asn Leu Ala	
180 185 190	
Trp Asn Lys Ile Ala Ile Ile His Pro Asn Ala Phe Ser Thr Leu Pro	
195 200 205	
Ser Leu Ile Lys Leu Asp Leu Ser Ser Asn Leu Leu Ser Ser Phe Pro	
210 215 220	
Ile Thr Gly Leu His Gly Leu Thr His Leu Lys Leu Thr Gly Asn His	
225 230 235 240	
Ala Leu Gln Ser Trp Ile Ser Ser Glu Asn Phe Pro Glu Leu Lys Val	
245 250 255	
Ile Glu Met Pro Tyr Ala Tyr Gln Cys Cys Ala Phe Gly Val Cys Glu	
260 265 270	
Asn Ala Tyr Lys Ile Ser Asn Gln Trp Asn Lys Gly Asp Asn Ser Ser	
275 280 285	
Met Asp Asp Leu His Lys Lys Asp Ala Gly Met Phe Gln Ala Gln Asp	
290 295 300	
Glu Arg Asp Leu Glu Asp Phe Leu Leu Asp Phe Glu Glu Asp Leu Lys	
305 310 315 320	
Ala Leu His Ser Val Gln Cys Ser Pro Ser Pro Gly Pro Phe Lys Pro	
325 330 335	
Cys Glu His Leu Leu Asp Gly Trp Leu Ile Arg Ile Gly Val Trp Thr	
340 345 350	

Ile Asn Val Leu Ala Leu Ile Ile Val Asn Ala Leu Val Ile Ser Thr Val
 395 400 405 410 415 420 425
 Phe Asn Ser Ile Leu Tyr Ile Ser Pro Ile Ile Lys Leu Ile Gly Val
 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 499 500 501 502 503 504 505 506 507 508 509 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 599 600 601 602 603 604 605 606 607 608 609 609 610 611 612 613 614 615 616 617 618 619 619 620 621 622 623 624 625 626 627 628 629 629 630 631 632 633 634 635 636 637 638 639 639 640 641 642 643 644 645 646 647 648 649 649 650 651 652 653 654 655 656 657 658 659 659 660 661 662 663 664 665 666 667 668 669 669 670 671 672 673 674 675 676 677 678 679 679 680 681 682 683 684 685 685 686 687 688 689 689 690 690

• 210> 9
 • 211> 2467
 • 212> DNA
 • 213> human

• 4000> 1

daaaagdqda aagaaaaaaaaaa dggaaatccca aadadacaaga qaaadcaaat gggadtqdaa	60
ggagggadqa ctcccttttata actgtctaacc ttgcacacac aaataacacaa caaccactqt	120
gagctgtatq ccattcacaa accaaagaccc aatttttactc actttcatia atcagtttqct	180
cagataaaaaa qaaatdacat ctgttctat ctttcttctac ctcttaattt ttccaaaaata	240
tttttctcat ccccccttggas aaaaatgtccaa ctactccattt ctcttatttc cctgtgggaa	300
catcacaaaaa tcctttdctc adttctctca ctgttaaccat ttccacccatc ccggdaatca	360
ccccatqag qccaaactgtg qccacaaacaa tggatdtcc atccaaatttg acaaaaatattt	420
tgcctacttac tacaaaaatcg atccccatc tccttttgag qccaaaaacac ctccatcttt	480

<210> 6
<211> 757
<212> PRT
<213> human

<400> 5

```

Met Thr Ser Gly Ser Val Phe Phe Tyr Ile Leu Ile Phe Gly Lys Tyr
   1           5           10          15
Phe Ser His Gly Gly Gln Asp Val Lys Cys Ser Leu Gly Tyr Phe
   20          25          30
Pro Cys Gly Asn Ile Thr Lys Cys Leu Pro Gln Leu Leu His Cys Asn
   35          40          45
Gly Val Asp Asp Cys Gly Asn Gln Ala Asp Glu Asp Asn Cys Gly Asp
   50          55          60
Asn Asn Gly Trp Ser Met Gln Phe Asp Lys Tyr Phe Ala Ser Tyr Tyr
   65          70          75          80
Lys Met Thr Ser Gln Tyr Pro Phe Glu Ala Glu Thr Pro Glu Cys Leu
   85          90          95
Val Gly Ser Val Pro Val Gln Cys Leu Cys Gln Gly Leu Glu Leu Asp
   100         105         110
Cys Asp Glu Thr Asn Leu Arg Ala Val Pro Ser Val Ser Ser Asn Val
   115         120         125
Thr Ala Met Ser Leu Gln Trp Asn Leu Ile Arg Lys Leu Pro Pro Asp
   130         135         140

```


Ser Ala Ile Thr Ala Thr Ser Ile Arg Asn Glu Val Lys Gln Met
 610 615 620
 Ile Leu Ala Lys Arg Phe Phe Phe Ile Val Phe Thr Asp Ala Leu Cys
 625 630 635 640
 Trp Ile Pro Ile Phe Val Val Lys Phe Leu Ser Leu Leu Gln Val Glu
 645 650 655
 Ile Pro Gly Thr Ile Thr Ser Trp Val Val Ile Phe Ile Leu Pro Ile
 660 665 670
 Asn Ser Ala Leu Asn Pro Ile Leu Tyr Thr Leu Thr Thr Arg Pro Phe
 675 680 685
 Lys Glu Met Ile His Arg Phe Trp Tyr Asn Tyr Arg Gln Arg Lys Ser
 690 695 700
 Met Asp Ser Lys Gly Gln Lys Thr Tyr Ala Pro Ser Phe Ile Trp Val
 705 710 715 720
 Glu Met Trp Pro Leu Gln Glu Met Pro Pro Glu Leu Met Lys Pro Asp
 725 730 735
 Leu Phe Thr Tyr Pro Cys Glu Met Ser Leu Ile Ser Gln Ser Thr Arg
 740 745 750
 Leu Asn Ser Tyr Ser
 755

- 210: 7
- 211: 3584
- 212: DNA
- 213: human

• 400: 7

ctgctttgt	aactgtctaaga	ttgcagacag	aaatagcaca	caaccactgt	gagctgtatg	60
cgattcagaa	accaagacca	aattttgttc	acttttatta	atcagttgt	cagatagaag	120
gaaatgacat	cttggttctgt	cttcctctac	atcttaattt	ttggaaaata	tttttctcat	180
gggggtggac	aggatgtcaa	gtgcctccctt	ggctatttcc	cctgtggaa	catcacaaag	240
tgcttgcctc	agctcctgca	ctgttaacgg	gtggacgact	gcggaaatca	ggccgatgag	300
gacaactgtg	tggtgtgttt	gtgcctagtgc	atgtctttgc	caggtctgga	gcttgactgg	360
atgaaaccat	ttacgagttt	tccatcggtt	tcttcaaatg	tgatgtcaat	gtcacttcag	420
tggaaactta	taagaaaact	tcctctgtat	tgcttcaaga	attatcatga	tcttcagaag	480
ctggaccttc	aaaacaataa	gattacatcc	atctccatct	atgttttcag	aggactgaat	540
agccttacta	aactgtatct	cagtcataac	agaataaacct	tcttgaagcc	gggtgttttt	600
gaagatcttc	acagactaga	atggctgata	attgaqadata	atcaccttag	tcaattttcc	660
ccaccaacat	tttatggact	aaatctttt	attctcttag	tcttgcataa	taacgtcttc	720
acccgttia	ctgataaaacc	tcttgtcaa	cacatgccaa	gactacattg	gctggacttt	780
gaaggcaacc	atatccataa	tttaagaaat	tttgcattttt	tttcttgcag	taattttact	840
gtttttgtqa	tgaggaaaaa	caaaaattaa	cacttaaatg	aaaatactttt	tgcaccccttc	900
cagaaactgg	atgaaatttga	ttttaggaagt	aataagattt	aaaatcttc	accgcattata	960
ttcaaggazz	tgaaggagat	gtcacaattt	aatctttctt	ataatccaaat	caagaaaaatt	1020
caagcaaaacc	aatttgatta	tcttgcataa	ctcaagtctc	tcagcctaga	agggattgaa	1080
atttccaaata	tccaacaaag	gtgtttttaga	ctcttttatga	atctctctca	catatatattt	1140
aagaaattcc	agtactgtgg	gtatgcacca	catgttcgca	gctgtaaacc	aaacactgtat	1200
ggaatttcat	ctcttagagaa	tctttggca	agcattattt	agagagtatt	tgtctgggtt	1260
gtatctgcag	ttacctgttt	tggaaacatt	tttgcatttt	gcatgcgacc	ttatatcagg	1320
tctgagaaca	agctgtatgc	catgtcaatc	atttctctct	gctgtgccga	ctgcttaatg	1380
ggaatattat	tattcgttat	cgaggcttt	gacctaaagt	ttctgtggaga	atacaataag	1440
catgcgcagc	tgtggatgga	gagtactcat	tgtcagctt	tagatcttt	ggccattctg	1500
tccacagaag	tatcagtttt	actgttaaca	tttctgacat	tggaaaata	catctgcatt	1560
gtctatccctt	ttagatgtqt	gagacctgga	aaatgcacaa	caattacagt	tctgattctc	1620
atttggatta	ctggttttat	agtqcttgc	attccatgt	gcaataagga	atttttcaaa	1680
aactactatg	gcaccaatgg	agtatgtttc	cctcttcatt	cagaagatac	agaaagatatt	1740
ggagccccaga	tttatttcaat	ggcaattttt	cttggattta	atttggccgc	atttatcatc	1800
atagtttttt	cctatggaaq	catgttttat	agtgttcatc	aaagtgcctat	aacagcaact	1860
gaaatacggaa	atcaagttaa	aaaagagatg	atccttgcca	aacgtttttt	ctttatagta	1920

- 210: 8
· 211: 722
· 212: PRT
· 213: human

400: 3

Met	Thr	Ser	Gly	Ser	Val	Phe	Phe	Tyr	Ile	Leu	Ile	Phe	Gly	Lys	Tyr
1					9				10				11		
Phe	Ser	His	Gly	Gly	Gly	Gln	Asp	Val	Lys	Cys	Ser	Leu	Gly	Tyr	Phe
						26			25				30		
Pro	Cys	Gly	Asn	Ile	Thr	Lys	Cys	Leu	Pro	Gln	Leu	Leu	His	Cys	Asn
						35			40				45		
Gly	Val	Asp	Asp	Cys	Gly	Asn	Gln	Ala	Asp	Glu	Asp	Asn	Cys	Val	Val
						50			55				60		
Val	Leu	Cys	Gln	Cys	Met	Ser	Leu	Pro	Gly	Leu	Glu	Leu	Asp	Trp	Met
						65			70				75		80
Lys	Pro	Phe	Thr	Ser	Val	Pro	Ser	Val	Ser	Ser	Asn	Val	Thr	Ala	Met
						85				90				95	
Ser	Leu	Gln	Trp	Asn	Leu	Ile	Arg	Lys	Leu	Pro	Pro	Asp	Cys	Phe	Lys
						100			105				110		
Asn	Tyr	His	Asp	Leu	Gln	Lys	Leu	Asp	Leu	Gln	Asn	Asn	Lys	Ile	Thr
						115			120				125		
Ser	Ile	Ser	Ile	Tyr	Ala	Phe	Arg	Gly	Leu	Asn	Ser	Leu	Thr	Lys	Leu
						130			135				140		
Tyr	Leu	Ser	His	Asn	Arg	Ile	Thr	Phe	Leu	Lys	Pro	Gly	Val	Phe	Glu
						145			150				155		160
Asp	Leu	His	Arg	Leu	Asn	Trp	Leu	Ile	Ile	Glu	Asp	Asn	His	Leu	Ser
						165				170				175	
Arg	Ile	Ser	Pro	Pro	Thr	Phe	Tyr	Gly	Leu	Asn	Ser	Leu	Ile	Leu	Leu
						180			185				190		

Val Leu Met Arg Arg Thr Leu Thr Arg Leu Ile Asp Lys Pro Leu Cys
 180 100 160
 Gin His Met Ile Arg Leu His Trp Leu Asp Leu Glu Gly Asn His Ile
 210 215 220
 His Asn Leu Arg Asn Leu Thr Phe Ile Ser Cys Ser Asn Leu Thr Val
 220 230 235 240
 Leu Val Met Arg Lys Lys Ile Asn His Leu Asn Glu Asn Thr Phe
 245 250 255
 Ala Pro Leu Gin Lys Leu Asp Glu Leu Asp Leu Glu Ser Asn Lys Ile
 260 265 270
 Glu Asn Leu Pro Pro Leu Ile Phe Lys Asp Leu Lys Glu Leu Ser Gln
 275 280 285
 Leu Asn Leu Ser Tyr Asn Pro Ile Gin Lys Ile Gln Ala Asn Gln Phe
 290 295 300
 Asp Tyr Leu Val Lys Leu Lys Ser Leu Ser Leu Glu Gly Ile Glu Ile
 305 310 315 320
 Ser Asn Ile Gin Gin Arg Met Phe Arg Pro Leu Met Asn Leu Ser His
 325 330 335
 Ile Tyr Phe Lys Lys Phe Gln Tyr Cys Gly Tyr Ala Pro His Val Arg
 340 345 350
 Ser Cys Lys Pro Asn Thr Asp Gly Ile Ser Ser Leu Glu Asn Leu Leu
 355 360 365
 Ala Ser Ile Ile Gln Arg Val Phe Val Trp Val Val Ser Ala Val Thr
 370 375 380
 Cys Phe Gly Asn Ile Phe Val Ile Cys Met Arg Pro Tyr Ile Arg Ser
 385 390 395 400
 Glu Asn Lys Leu Tyr Ala Met Ser Ile Ile Ser Leu Cys Cys Ala Asp
 405 410 415
 Cys Leu Met Gly Ile Tyr Leu Phe Val Ile Gly Gly Phe Asp Leu Lys
 420 425 430
 Phe Arg Gly Glu Tyr Asn Lys His Ala Gln Leu Trp Met Glu Ser Thr
 435 440 445
 His Cys Gln Leu Val Gly Ser Leu Ala Ile Leu Ser Thr Glu Val Ser
 450 455 460
 Val Leu Leu Leu Thr Phe Leu Thr Leu Glu Lys Tyr Ile Cys Ile Val
 465 470 475 480
 Tyr Pro Phe Arg Cys Val Arg Pro Gly Lys Cys Arg Thr Ile Thr Val
 485 490 495
 Leu Ile Leu Ile Trp Ile Thr Gly Phe Ile Val Ala Phe Ile Pro Leu
 500 505 510
 Ser Asn Lys Glu Phe Phe Lys Asn Tyr Tyr Gly Thr Asn Glu Val Cys
 515 520 525
 Phe Pro Leu His Ser Glu Asp Thr Glu Ser Ile Gly Ala Gln Ile Tyr
 530 535 540
 Ser Val Ala Ile Phe Leu Gly Ile Asn Leu Ala Ala Phe Ile Ile Ile
 545 550 555 560
 Val Phe Ser Tyr Gly Ser Met Phe Tyr Ser Val His Gln Ser Ala Ile
 565 570 575
 Thr Ala Thr Glu Ile Arg Asn Gln Val Lys Lys Glu Met Ile Leu Ala
 580 585 590
 Lys Arg Phe Phe Phe Ile Val Phe Thr Asp Ala Leu Cys Trp Ile Pro
 595 600 605
 Ile Phe Val Val Lys Phe Leu Ser Leu Leu Gln Val Glu Ile Pro Gly
 610 615 620
 Thr Ile Thr Ser Trp Val Val Ile Phe Ile Leu Pro Ile Asn Ser Ala
 625 630 635 640
 Leu Asn Pro Ile Leu Tyr Thr Leu Thr Thr Arg Pro Phe Lys Glu Met
 645 650 655

Ile His Arg Ile Trp Tyr Asn Tyr Arg Glu Arg Ile Ser Met Asp Ser
660 665 670
Lys Glu Cln Lys Thr Tyr Ala Pro Ser Ile Trp Val Glu Met Trp
675 680 685
Pro Leu Glu Glu Met Pro Pro Glu Leu Met Lys Pro Asp Leu Phe Thr
690 695 700
Tyr Pro Cys Glu Met Ser Leu Ile Ser Glu Ser Thr Arg Leu Asn Ser
705 710 715 720
Tyr Ser

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/06573

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 14/705; C12N 15/12, 15/63, 15/70, 15/79
US CL :530/350; 435/69.1, 252.3, 254.11, 320.1, 325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 435/69.1, 252.3, 254.11, 320.1, 325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Biosis, Medline, WPI
search terms: G-protein coupled receptor, Leucine rich repeats, Gonadotropin receptor, Thyrotropin receptor

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,614,363 A (CONE) 25 March 1997, entire document.	1-11
X, P ----- Y, P	US 5,858,716 A (ELSHOURBAGY et al.) 12 January 1999, columns 20-30, entire document.	11 ----- 1-10
X -- Y	HWANG et al. Analysis of Expressed Sequence Tags from a Fetal Human Heart cDNA Library. Genomics. 1995, Vol. 30, pages 293-298, entire document.	5, 7, 11 ----- 1-4, 6, 8-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
E earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	"A"	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 JUNE 1999

Date of mailing of the international search report

02 AUG 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Sally P. Teng

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No
PCT/US99/06573

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows.

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, drawn to nucleic acids encoding LGR4, the LGR4 polypeptide, and method of using the LGR4 nucleic acid.

Group II, claims 1-11, drawn to nucleic acids encoding LGR5, the LGR5 polypeptide and method of using the LGR5 nucleic acid.

Group III, claims 1-11, drawn to nucleic acid encoding LGR6, the LGR6 polypeptide, and method of using the LGR6 nucleic acid.

Group IV, claims 12 and 13, drawn to antibody that binds to LGR4.

Group V, claims 12 and 13, drawn to antibody that binds to LGR5.

Group VI, claims 12 and 13, drawn to antibody that binds to LGR7.

Group VII, claims 14-17, drawn to transgenic animal model containing an altered LGR4 gene.

Group VIII, claims 14-17, drawn to transgenic animal model containing an altered LGR5 gene

Group IX, claims 14-17, drawn to transgenic animal model containing an altered LGR7 gene

Group X, claim 18, drawn to a method of screening for a ligand for LGR4.

Group XI, claim 18, drawn to a method of screening for a ligand for LGR5.

Group XII, claim 18, drawn to a method of screening for a ligand for LGR7.

Each of the claims 1-18 is in three different groups because LGR4, LGR5, and LGR7 are structurally and functionally distinct polypeptides.

The inventions listed as Groups I-XII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of Group I is the nucleic acid sequence encoding LGR4. The special technical feature of Group II is the nucleic acid sequence encoding LGR5. The special technical feature of Group III is the nucleic acid sequence encoding LGR7. The special technical feature of Group IV is the antibody that binds to LGR4 but does not have the amino acid sequence of LGR4. The special technical feature of Group V is the antibody that binds to LGR5 but does not have the amino acid sequence of LGR5. The special technical feature of Group VI is the antibody that binds to LGR6 but does not have the amino acid sequence of LGR6. The special technical feature of Group VII is a transgenic animal containing an altered LGR4 gene. The special technical feature of Group VIII is a transgenic animal containing an altered LGR5 gene. The special technical feature of Group IX is a transgenic animal containing an altered LGR7 gene. The special technical feature of Group X is a method of screening for a ligand that binds LGR4. The special technical feature of Group XI is a method of screening for a ligand that binds LGR5. The special technical feature of Group XII is a method of screening for a ligand that binds LGR7. The special technical feature of each group is not the same or does not correspond to the special technical feature of any other group because the products of Groups I-IX are structurally and functionally distinct and the methods of Groups I-III and X-XII are distinct methods of using different starting reagent for accomplishing different goals. The groups are not linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/06573

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	HSU et al. Charcterization of Two LGR Genes Homologous to Gonadotropin and Thyrotropin Receptors with Extracellular Leucine-Rich Repeats and a G Protein-Coupled, Seven Transmembrane Region. Molecular Endocrinology. December 1998, Vol. 12, No. 12, pages 1830-1845, especially pages 1831-1837.	1-11